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The major histopathologic hallmark of Alzheimer’s disease (AD) is the presence 
of (3-amyloid plaques that are often associated with reactive microglia in the brain. It has 
been suggested modulating the microglial phenotype to attenuate an inflammatory 
response may prove to be useful in determining therapies for prevention or delay of the 
disease. My dissertation supports he hypothesis that Ap stimulates microglial activation 
through a specific tyrosine kinase-dependent response involving the Src kinase family. 
Using primary mouse microglia we observed that both fibrillar and oligomeric Ap 
stimulated increased microglial protein phosphotyrosine levels including active levels of 
the kinase Src and a subsequent increase in secretion of the cytokine, tumor necrosis 
factor alpha (TNFa). This response was attenuated by using a Abl/Src family kinase 
inhibitor, dasatinib. Intracerebroventricular infusions of AP oligomer into C57BL/6 adult 
mice elevated hippocampal phosphotyrosine levels and microgliosis that were attenuate 
by dasatinib treatment. To evaluate the efficiency of dasatinib in a relevant transgenic 
model of AD, drug was subcutaneously infused into 13-month old APP/PS1 transgenic 
mice. Behavioral testing using T-maze showed better performance from dasatinib infused 
mice as compared to vehicle treated and control animals. Biochemical analyses 
demonstrated that dasatinib infused animals had lower total protein phosphotyrosine and 
pSrc levels in the hippocampus. Dasatinib is an FDA approved drug for treating chronic 
myeloid leukemia and can cross the blood brain barrier. Our demonstration of the 
microglial inhibitory action of this drug defines a novel use. Based upon the observation
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that AD brains showed increase in active, phosphorylated Lyn levels in reactive 
microglia, this kinase may also represent a possible microglial inhibitory target as well. 
Following a high throughput screening kinase assay, four drugs were identified. One 
compound LDDN-0003499 inhibited total protein phosphotyrosine as well as active pLyn 
levels in BV2 microglial cell line. LPS stimulated microglia treated with LDDN-0003499 
demonstrated attenuation of TNF-a levels secretion. Collectively, our data supports the 
idea that non-receptor tyrosine kinase inhibition could be an important therapeutic goal 





Alzheimer’s disease is the most common form of dementia. It affects mainly the 
elderly with a prevalence of 5% after 65 years of age and increases to about 30% at 85 
years of age. AD is mainly characterized by cognitive impairment that affects thinking 
and behavior, severe enough to interfere with daily life (McKhann et al., 1984). It is a 
progressive form of disease that gets worse over time. At present, 5.3 million Americans 
are suffering from AD, with over 26 million people affected worldwide. According to the 
World Alzheimer’s Report, the total estimated costs of dementia in US was $604 billion 
in 2010 with about 70% of that occurring in Western Europe and North America. Apart 
from the huge economic burden, this disease presents a tremendous amount of emotional 
and physical stress to not only the patients but also the care-givers of people suffering 
with Alzheimer’s disease.
The disease was first described in 1906 by German psychiatrist and 
neuropathologist, Alois Alzheimer, when he observed in a patient, strange behavioral 
symptoms, including loss in short-term memory. Brain autopsy showed various 
abnormalities including a thinner cerebral cortex than normal and the presence of senile 
plaques and neurofibrilary tangles. Although the cause and progression of
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Alzheimer’s disease are not well understood, it has been very well established that the 
histopathology of AD consists of these two distinct characteristics, the presence of 
tangles and plaques (Dickson, 1997). These neurofibrilary tangles are mainly found in 
neurons in the brain regions affected by AD and are composed of protein tau, that is 
aggregated as paired helical filaments (PHF) (Hernandez and Avila, 2007). Tau is 
normally associated with microtubules that represent a component of structural support 
for intracellular transport (Weingarten et al., 1975; Drubin and Kirschner, 1986). Under 
normal conditions, tau has a role in stimulation and stabilization of microtubules. 
However in AD, tau is hyperpho sp horylated which inhibits its ability to provide 
microtubule assembly and it aggregates as insoluble deposits within the cells (Grundke- 
Iqbal et al., 1986). The other major histopathological marker of AD is the presence of 
senile plaques, which are insoluble fibrous protein aggregates of amyloid-|3 peptide 
(Selkoe, 1994). This peptide is the cleavage product of a transmembrane integral protein, 
amyloid precursor protein. Plaques and tangles are predominantly found in frontal and 
temporal cortex regions of the brain, including the memory and visuospatial center, the 
hippocampus (Ray et al., 1998). Whether plaques and tangles play a causative or 
consequential role in the progression of Alzheimer’s disease is still not well understood.
Clinically, Alzheimer’s disease progression is marked by different stages of very 
mild/mild cognitive impairments (MCI), mild, moderate and severe dementia (Morris, 
1993; Petersen et al., 1999). These stages correlate with increasing abundance of 
amyloid-plaques, neurofibrilary tangles and loss of neuronal and synaptic markers. 
Figure 1 adapted from (Perrin et al., 2009) illustrates the progression of changes of the 
various characteristic biomarkers of AD over time with relation to the appearance of
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clinical stages in an AD brain. Amyloid-fi plaques occur in the pre-clinical stages of AD 
for 10-15 years, eventually leading to damages in neuronal integrity (Morris, 1993). 
Neuronal loss is associated with onset of dementia as well as an increase in neurofibrilary 
tangles. The major biomarkers of AD include an increase in CSF tau and phosphorylated 
tau, a decrease in CSF Af)42, microgliosis, inflammation, increase in markers oxidative 
stress, brain atrophy and genetic predisposition (Sunderland et al., 2003; Galimberti et ah, 
2008; Kauwe et ah, 2009; Reddy et ah, 2009). For diagnostic purposes, advanced medical 
imaging techniques like computer tomography (CT) or magnetic resonance imaging 
(MRI) and positron emission tomography (PET) can be used to determine the cerebral 
topography, but it is difficult to predict the earliest stages of AD. These diagnostic tools 
may predict the subtype of dementia or conversion from MCI to AD. However, apart 
from genetic predisposition, it is difficult to monitor the occurrence of AD progression in 
the early stages of the disease (Craig-Schapiro et ah, 2009; Perrin et ah, 2009)
AD can be classified into two forms, Familial Alzheimer’s disease (FAD) and the 
Sporadic Alzheimer’s disease (SAD). The familial form of the disease is uncommon and 
accounts for 5% of the cases and is usually defined at an earlier age. Also known as 
Early-onset AD, autosomal dominant mutations in APP, Presenilin 1 (PSEN1) and 
Presenilin 2 (PSEN 2) genes has been linked with the familial form of the disease. The 
sporadic form of AD accounts for 95% of the cases and has been linked to a number of 
environmental factors along with synergistic actions from genetic factors. These include 
cardiovascular diseases. Type 2 diabetes, mid-life obesity, increased age as well as
3
polymorphisms in apolipoprotein E (ApoE) as risk factors (Stritlmatter and Roses, 1996; 
Lendon etal., 1997; Patterson et al., 2008).
Figure 1. Proposed changes in biomarkcrs in relation to the time course of 
pathological and clinical stages (Adapted with permission from (Perrin et al., 2009))
APP and Amyloid-p peptide
A tremendous amount of research has been performed to try to identify the role of 
amyloid-p peptide in the pathogenesis of Alzheimer’s disease. The peptide is derived 
from amyloid precursor protein (APP) which is ubiquitously expressed in neuronal and 
non-neuronal cells (Selkoe, 1994). Non-amyloidogenic cleavage of APP by a-secretase at 
a site within the Ap domain, leads to the production of the soluble APP fragment, sAPPa, 
and prevents the formation of AP peptide (Lammich et al., 1999). But the amyloidogenic 
pathway of APP cleavage by p-seeretase followed by gamma-secretase action generates 
the amyloid-P (AP) peptide (Fig. 2) (Gandy, 2005). Ap is a 4KDa peptide with
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microheterogeneiety in amino acid sequence with two physiologically relevant forms 
A(3 (_4o and A[51 -42. AP1-40 is the most abundant form of the Afl present while A[51.42 form is 
more prone to aggregation (Jarrett et al., 1993b; Yin et ah, 2007). Ap42 readily 
multimerizes to form oligomers, then fibrils, and fully detergent resistant plaque 
aggregates (Gandy, 2005). A[3.42, the more fibrillogenic form, is thus associated with 
disease states, Mutations in APP associated with early-onset Alzheimer's have been noted 
to increase the relative production of A[342 perhaps leading to accommodation of plaque 
deposition and the early age of disease (Yin et ah, 2007).
One of the leading theories behind understanding of the causes of AD pathology 
is the amyloid cascade hypothesis (Hardy, 2006). This theory was proposed in 1992 by 
Hardy and Higgins and has remained controversial over the years (Hardy and Higgins,
1992; Hardy, 1999, 2002). According to the hypothesis, A(3 plaque deposition is the main 
cause of AD pathogenesis. APP proteolysis leading to accumulation and deposition of A (3 
plaques is the initiating event that then leads to Af) dependent synaptic loss, neuritic 
injury, altered signaling events and subsequent formation of neurofibrilary tangles and 
cell death. Vascular damage and dementia follow as a direct effect of the deposition 
(Hardy and Selkoe, 2002; Hardy, 2006). Because A|3 peptide forms the fibrillar core of 
the senile plaques in both sporadic and autosomal dominant disease it has been 
hypothesized that fibrillar A [3 deposition is mechanistically critical for disease (Jarrett et 
ah, 1993a; Pike et ah, 1993). However, in recent years, evidence suggests a direct 
correlation between cognitive impairment and synaptic loss with the levels of soluble 





Figure 2: Schematic of Aniyloidogenic APP processing
et al., 1999). Oligomeric Af3 has been shown to be neurotoxic and synaptotoxic in vitro 
studies as well (McLean et al., 1999; Sondag et al., 2009). A(3 oligomers have also been 
linked to gliotic pro-inflammatory changes in vitro (Roller et al., 1996; Cleary et al.,
2005; Klyubin et al., 2005; Leslie et al., 2006; Klyubin et al.. 2008). The exact 
contribution of the particular form of A|3 to disease, whether oligomeric or fibrillar, is yet 
to be fully defined. However, the issue remains that in order to identify a prevention or 
treatment therapy for AD, the role of Ap and the mechanism behind its gliotic and 
neuronal actions need to be fully understood.
Microglia and AD
Microglia are the resident macrophages of the brain and the spinal cord. They
form the first line of immune defense in the central nervous system. These cells constitute
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about 5-20% of ail glial cells (Lawson et ai., 1992). In early stages of brain development, 
microglia generally represent an “amoeboid” phenotype. They show a macrophage-like 
morphology with a larger cell body and shorter processes (Ling, 1979). As the brain 
develops, these microglia obtain a “ramified” morphology. These are the resting 
microglia in a normal brain, with relatively longer processes and smaller cell bodies. In 
cases of brain injury, or other neurodegenerative diseases, ramified microglia may 
transform into activated states, also called “reactive microglia” (Nakajima and Kohsaka, 
2001). These are morphologically distinct with longer, finger-like projections. The 
reactive microglia become proliferative at the affected site. Activated microglia have 
been implicated to play cytotoxic and inflammatory roles in the CNS (Poli, 1998; Weldon 
et a!., 1998; Nakajima and Kohsaka, 2001; Rogers et al., 2002; Schlachetzki and Hull, 
2009).
Microglia belong to the mononuclear phagocytic system, expressing characteristic 
markers of phagocytes and immune cells, such as complement components and their 
receptors, MHC glycoproteins and scavenger receptors (McGeer and McGeer, 1999;
Streit et al., 2004). Activated microglia are known to secrete cytokines as well as toxic 
free radicals (Poli, 1998; Weldon et al., 1998; Akiyama et al., 2000; Jara et al., 2007). In 
neurodegenerative diseases, microglia are known to show increased secretion of pro- 
inflammatory cytokines, chemokines and free radicals and reduced clearance of 
pathological protein aggregates (like A[3) and cell debris, thus contributing to disease 
pathogenesis (Dickson et al., 1993; Yates et al.. 2000; Tuppo and Arias, 2005; Block et 
al., 2007).
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1 he presence ot increased number of reactive microglia has been very well 
characterized in Alzheimer’s disease (Fig. 3). Besides the accumulation of plaques and 
tangles it has been shown in both human disease and transgenic mouse models, that 
reactive microglia numbers are increased compared to non-demented controls and wild- 
type mice, respectively (McGeer et al., 1987; Akiyama and McGeer, 1990; Cras et al., 
1990; Styren et al., 1990; Frautschy et al., 1998; Stalder et al., 1999; Wegiel et al., 2001; 
Sasaki et al., 2002; Wegiel et al., 2003). The morphologically distinct, activated 
microglia are commonly associated with A(3 fibril containing plaques (Itagaki et al.,
1989; Mattiaee et al., 1990; Perlmutter et al., 1990; Mackenzie et al., 1995; Sasak. et al., 
1997; Akiyama et al., 1999; Benzing et al., 1999; Morgan et al., 2005; Meyer-Luehmann 
et al., 2008). Numerous in vitro studies have demonstrated that AP Fibrils can directly 
stimulate microglia to acquire a pro-inflammatory phenotype (Banati et al., 1993: Del Bo 
et al., 1995; Giulian et al„ 1995; Klegeris et al.. 1997; Combs et al., 2000; Combs et al., 
2001a; Combs et al., 2001b). However oligomeric AP conformations have also been 
reported to stimulate gliosis (Martin et al.. 1994; Sasaki et al., 1997; Sondag et al., 2009). 
Indeed, up to 70% of diffuse plaques in non-demented aged individuals contain microglia 
(Sasaki et al., 1997) suggesting that microglial interaction with nonfibrillar peptide is 
common. Work from primates even indicates that gliosis precedes fibrillar plaque 
deposition (Martin et al., 1994). Therefore, the fibrillar, insoluble form of the peptide 
may not be the only substrates mediating neuronal death/dysfunction. More importantly, 




Figure 3. Presence of reactive microglia in AD brain
Anti-inflammatory approach to AD
A plethora of data over the past 2 decades have led to the conclusion that
neuroinflammation forms an integral component of the pathogenesis of AD (Akiyama el
al., 2000; Strcit et al., 2004; Tuppo and Arias. 2005; Rojo et al., 2008; Agostinho et al.,
2010; McNaull et al., 2010; Schwab et al., 2010). Up regulation of various pro-
inflammatory cytokines has been widely reported in AD patients (McGeer and McGeer,
1999: Streit et al., 2001; Szczepanik et al., 2001; Moore and O'Banion. 2002; Wilson et
al., 2002; Streit et al., 2004; Tuppo and Arias, 2005; Galimberti et al., 2008; Combs,
2009; McNaull et al., 2010). Microglia cultured from AD brains demonstrate marked
chemotaxis to AfS deposits (Rogers and L.ue, 2001) Microglia adhesion to A|) fibril
coated surfaces substantially increases reactive oxygen species production (El Khoury et
al., 1996). An increase in secretion of pro-inflammatory cytokines 1L-Ip, IE-6 and TNF-
a, chemokines IE-8, macrophage and MEP-ln have been observed in microglia
interacting with Afi deposits (Rogers and l.ue. 2001). Pro-inflammatory changes have
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been widely reported in transgenic mouse models of AD as well. Brains of Tg 2576, 
TgAPPsw, PSl/APPsw and triple transgenic mice (3XTg-AD), have all been reported to 
have elevated levels of pro-inflammatory cytokines including IFN-y, IL-12, TNF-a, IL- 
6,lL-ip, TGF-(3, IL-10, MCP-1 and GM-CSF (Benzing et al., 1699; Apelt and Schliebs, 
2001; Abbas et al., 2002; Janelsins et al., 2005; Patel et al., 2005).
Modulation of inflammatory activity in these mouse models produces changes in 
their AD-like pathology. For example, use of dominant negative-TNF inhibitors in triple 
transgenics prevents intraneuronal A(3 accumulation (McAlpine et al., 2009). IFN-y 
knockdown reduces A(3 plaque load and gliosis in Tg2576 mice (Yamamoto et a l, 2007). 
Up-regulating pro-inflammatory pathways has also been reported to give rise to AD 
pathology. For example, overexpression of CCL2 (MCP-1) increases microglial 
activation and A|3 deposition in APP/PS1 mice (Yamamoto et al., 2005).
Based upon the idea that manipulating microglial activity in various mouse 
models can affect disease histopathology, it is reasonable to expect that similar alteration 
of microglial phenotype will affect human disease. A number of epidemiological studies 
have demonstrated that long-term use of non-steroidal anti-inflammatory drugs 
(NSAIDs) could be helpful in reducing the risk of AD. The Rotterdam study in 2001 
showed that long-term use of ibuprofen reduced relative risk of developing AD to 0.2 
(95% Cl 0.05-0.83)(in't Veld et al., 2001). Use of ibuprofen. naproxen and indomethaein, 
all NSAIDs demonstrated lower incidences of AD in the Baltimore study of Aging 
(Stewart et al., 1997). Use of NSA1D was also associated with a decrease in microgliosis 
without affecting the A|) fibrillar plaque load (Mackenzie and Munoz, 1998). The most
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probable mechanism of action ofNSAIDs is inhibition of COX-2 activity and 
prostaglandin production, both linked to pro-inflammatory effects (McNaull et a!.. 2010). 
In late onset AD. COX-2 activity has been found to be elevated in humans and it as also 
been linked to APP processing and cognitive decline in animal models (Pasinetti and 
Aisen, 1998; Tuppo and Arias, 2005; Rojo et al., 2008; McNaull et al., 2010). Besides 
cox inhibition, NSAIDs have been proposed to work through inhibition of cytokine 
expression as well as modulation of y-secretase activity (Weggen et al. 003). Some 
NSAIDs are known to be PPAR-y agonists, modulating oxidative stress and inhibiting of 
expression of inflammatory genes (Lehmann et al., 1997; Landretl- and Heneka, 2001; 
McNaull et al., 2010). However, a number of studies using role >xib (Reines et al.,
2004), naproxen (Aisen et al., 200.3), diclofenac (Scharf et al., 1999), celecoxib (Soininen 
et al., 2007), dapsone (Eriksen et al.. 2003), hydroxychloroquine (Aisen et al., 2001) and 
nimesulide (Aisen et al., 2002) failed to slow progression of cognitive decline in patients 
with mild to moderate AD. A number of factors may be responsible for the failure or 
disappointing results in the clinical studies involving the use ofNSAIDs. These include 
inadequate drug penetration into the brain, inadequate doses and the variability in 
diagnosis and progression of AD in individuals (Rojo et al., 2008). Indeed a very recent 
study indicates that prolonged use ofNSAIDs decreases the incidence of AD when taken 
by only asymptomatic individuals (Breitner et al., 2011). This suggests that timing of 
anti-inflammatory use is critically important when considering any therapeutic strategies 
for AD.
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Structure, function and inhibition of Src family of tyrosine kinases
I yrosine kinases are enzymes that catalyze the transfer of phosphate groups from 
ATP to the tyrosine residues within proteins. Tyrosine kinases are part of the larger 
family of protein kinases. Proteins that become phosphorylated by tyrosine kinases, or by 
other kinases, allow for the signal transduction pathways that regulate many of the 
functions of cells. The Src family of tyrosine kinases (STKs) is a non-receptor kinase 
family with nine members: Lyn, Fyn, Lck, Hck, Fgr, Blk, Yrk, Yes and c-Src. c-Src 
(henceforth referred to a Src) is the best studied non-receptor tyrosine kinase and is 
commonly implicated in oncogenesis (Yeatman, 2004), cellular proliferation, survival, 
migration, and angiogenesis (Hanahan and Weinberg, 2000; Yeatman, 2004).
Proteins in the Src family have a conserved organization consisting of four Src 
homology (SIT) domains and a C-terminal segment containing a negative regulatory 
tyrosine residue (Tyr530) (Fig. 4). Src exists in both active and inactive conformations. 
Negative regulation occurs through phosphorylation of Tyr530, resulting in an 
intramolecular association between phosphorylated Tyr530 and the SH2 domain of Src, 
thereby locking the protein in a closed conformation. Further stabilization of the inactive 
state occurs through interactions between the SH3 domain and a proline-rich stretch of 
residues within the kinase domain (Sicheri and Kuriyan, 1997). Conversely, 
dephosphorylation of Tyr530 allows Src to assume an open conformation (Aleshin and 
Finn, 2010). Full activity requires additional autophosphorylation of the Tyr419 residue 
within the catalytic domain (Lowell, 2004). The intramolecular activity of Src is 
regulated by a balance between kinases and phosphatases including other receptor
12
tyrosine kinases such as epidermal growth factor receptor (EGFR), fibroblast growth 
factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) as well as 
direct binding of Focal Adhesion Kinases (FAK), that mainly act at the C-terminal 




Src inactivation Integrins (Src activation) Receptor Tyrosine kinase
Figure 4. Src activation and inactivation (adapted and modified from (Aleshin and 
Finn, 2010) and (Tatosyan and Mizenina, 2000)
As mentioned. Src activation is an important event in various cell processes in 
normal and malignant cells. Src plays a key role in regulation of cell adhesion and 
migration. Dynamic turnover of cell-cell (adherence junctions) and cell-matrix (focal 
adhesions) junctions is crucial for normal cellular adhesion, migration, and division 
(Biscardi et al., 1999; Playford and Schaller, 2004; Yeatman, 2004; McLean et al., 2005;
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Guarino, 2010). The subcellular localization of Src is critical to its function of regulating 
the assembly and disassembly of these junctions. An increase in Src signaling deregulates 
cell-cell adhesion. In association with FAK, Src mediates signals from extracellular 
matrix-integrin complexes to the cell interior, thereby influencing cell motility, survival, 
and proliferation (Roche et al., 1995; Prathapam et al., 2006). Src is also suggested to be 
involved in regulating cell cycle progression and mitogenesis (Weng et al., 1994; Roche 
et al., 1995; Prathapam et al., 2006). Src activation is associated with increased 
expression of proangiogenic cytokines such as VEGF and interleukin 8 (IL-8) (Kanda et 
al., 2007). Treatment with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] 
pyrimidine (PP2), a potent and selective inhibitor of SFKs, inhibits angiogenesis in vivo 
and blocks endothelial cell differentiation in vitro (Kilarski et al., 2003). Inhibiting Src 
blocks lL-8-mediated VEGFR2 activation and decreases vascular permeability (Yeh et 
al., 2004; Petreaca et al., 2007). Furthermore, SFKs are implicated in endothelial cell 
function, with inhibition of Src, Fyn, and Yes decreasing VEGF-induced endothelial cell 
migration (Werdich and Penn, 2005).
The Src family of tyrosine kinases has been identified as important for 
recruitment and activation of immune cells like monocytes, macrophages and neutrophils 
into pro-inflammatory sites. Several Src family members, Blk,Fgr, Hck, Lck, Lyn and 
Yes have been implicated in signaling responses in hematopoetic lineage cells (De 
Franceschi et ah, 1997; Lowell and Berton, 1999; Gardai et ah, 2002; Nijhuis et ah, 2002; 
Rane and Reddy, 2002). Src family members, Lck and Fyn are expressed in T-cells and 
are known to become activated directly downstream of the T-cell receptors (Barber et ah,
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1989). Macrophage and monocytes have been reported to express Fyn. Yes, Src, Hck and 
Lyn kinase (Okutani et al., 2006). LPS stimulation increases the expression of Hck in 
monocytes, human peripheral blood monocyte-derived macrophages and murine-bone 
marrow derived macrophages (Ziegler et al., 1988; Boulet et al., 1992; Beaty et al., 1994; 
Cohen, 2002). Lyn expression and activity is also increased in LPS stimulated 
macrophage and monocytes (Ziegler et al., 1988; Boulet et al., 1992; Beaty et ah, 1994). 
Blocking tyrosine kinase activity also reduces low-dose LPS induced TNF-a production 
as well as LPS-induced NF-kB translocation in macrophage (Khadaroo et ah, 2003; 
Khadaroo et ah, 2004). LPS stimulation recruits Src protein tyrosine kinases into the LPS 
receptor complex via CD 14 (Stefanova et ah, 1993). Other pro-inflammatory mediators 
have also been reported to be associated with Src family members, besides LPS. Src 
protein tyrosine kinases bind to IL-6 receptor b-chain, gpl 30 in macrophage (Schaeffer et 
ah, 2001). In addition to the involvement in pro-inflammatory pathways, Src kinases play 
critical roles in other cellular functions of macrophage. Src kinases arc known to 
associate with integrin heterodimers that play important role in migration and adhesion of 
macrophage (Suen et ah. 1999; Caveggion et ah, 2003). Macrophage with Src family 
kinases knockdown display alterations in cytoskeleton dynamics and polarization.
Abundant evidence of pharmacological intervention against Src protein tyrosine 
kinase in acute inflammation responses has been reported in vivo. Use of the selective Src 
kinase inhibitor PP1 in brain injury models in rats has been shown to reduce brain edema 
and mortality as well as suppressed vascular permeability in a mouse model of stroke 
(Paul et ah, 2001; Lusaka et ah, 2004; Lennmyr et ah, 2004). Another Src kinase
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inhibitor PP2. reduces alveolar macrophage priming in an acute lung injury model (Aid) 
in vivo (Khadaroo et al., 2004). Decreased LPS-induced acute lung injury and LPS- 
induced mortality were reported with PP2 injections as well (Severgnini et al., 2005).
With a key role in cell proliferation, invasion and metastasis, Src has been 
identified as a major target for therapeutic intervention with various Src inhibitors being 
identified for clinical purposes. One of the most studied Src inhibitors finds relevance in 
our study as well. Dasatinib, commercially available as Sprycel (Bristol-Myers Squibb) is 
an FDA approved drug for Chronic Myelogenous Leukemia. Dasatinib is an orally 
available, small-molecule Src/Abl inhibitor that has robust antitumor and antiproliferative 
activity against numerous hematologic and solid tumor cell lines (Lombardo et al., 2004; 
Das et al., 2006; Chang et al., 2008). In addition to inhibiting Src and Bcr-Abl in the 
subnanomolar range, dasatinib also variably inhibits other SFKs, c-KIT, PDGFR, and 
ephrin A2 (Chang et al., 2008). The mechanism of Src inhibition results from a hydrogen 
bond-mediated association with the ATP binding site, resulting in competitive restriction 
of ATP binding by Src (Lombardo et al., 2004). This compound emerged from a series of 
Lck inhibitors originally synthesized as anti-inflammatory compounds. Dasatinib (BMS- 
354825) is potent against cAbl and BCR-Abl, inhibiting the pure enzyme with an 1C50 of 
<1 nM(Jakubowska and Czyz, 2006). According to the Cancer Drug Information, 
National Cancer Institute, due to the activity of dasatinib against BCR-AbL especially its 
activity against mutant forms of BCR-Abl that are resistant to Gleevee treatment, Bristol- 
Myers developed this compound as a therapy against CML and ALL in pre-clinical and 
clinicai trials. As shown in vitro, Dasatinib was effective on patients harboring mutations
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resistant to Gleevec but not in those patients whose CML cells contained mutation T3151. 
This mutant proved to be resistant to Dasatinib in vitro (Quintas-Cardama et al., 2007). 
These results led to FDA approval of dasatinib for Cdeevec-resistant CML in June 2006 
at a recommended dose for CML(Gnoni et ah, 2011). Dasatinib is also known to cross the 
blood brain barrier, although the efficiency of the transport is not yet known (Porkka et 
ah, 2008).
During microglia stimulation, tyrosine phosphoi-ylation systems have been found 
to be particularly activated in vitro and in vivo (Tillotson and Wood, 1989b). Elevated 
protein phosphotyrosine levels have been reported, selectively in ramified microglia 
(Wood and Zinsmeister, 1991). Tyrosine phosphorylation of a variety of substrates is 
quantitatively enriched in microglia compared to other neural cel! types. Therefore, 
protein tyrosine kinases have been seen as reliable markers for microglial activation in 
Alzheimer’s disease (Karp et ah, 1994). In vitro studies using monocytic lineage cells 
(Combs et ah, 1999) as well as microglia (Sondag et ah, 2009) have supported these data 
by demonstrating that A(3 fibrils and oligomers stimulate a specific increase in overall 
protein tyrosine phosphorylation. This supports the idea that tyrosine kinase inhibition 
may be useful for attenuating microgliosis in AD.
Hypothesis
Microglial-dependent proinflammatory changes are a component of Alzheimer’s 
disease process suggesting that strategies to limit acquisition of a reactive phenotype may 
be therapeutically useful. However, in order to modulate microglial behavior during 
disease it is necessary to understand their source of stimulation and the resultant
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mechanism of activation. One possibility is that AfS peptide in both its fibrillar and 
oligomeric form may activate microglia during disease. As already mentioned, prior work 
from our lab as well as others has demonstrated the ability of fibrillar peptide to stimulate 
microglia. Prior work has shown that the oligomeric peptide is a potent proinilammatory 
stimulus also utilizing tyrosine kinase mechanism (Sondag el al., 2009). This increase in 
tyrosine kinase activity is required for subsequent secretion of the neurotoxic cytokine, 
TNFa. Ap oligomers were also shown to be toxic to cultured neurons only in the 
presence of microglia (Sondag et ah, 2009).
Therefore, targeting Ap oligomer and fibril dependent signaling mechanism in 
microglia, especially those including the Src family of kinases, presents a therapeutically 
attractive target to attenuate microgliosis in AD. This work aims to indentify Src kinase 
inhibitory properties of a commercially available cancer drug, dasatinib as well as 
characterizing novel Src kinase inhibitors, for attenuating Ap oligomer and fibril 
dependent microgliosis in various disease models including primary microglia cultures, 





Anti-oligomer antibody (111) and anti-fibril antibody (O.C.) have been previously 
described (Kayed et al., 2007). The anti-oligomer antibody (Al l )  was purchased from 
Invitrogen (Camarillo, CA). Anti-Ap, clones 6E10 and 4G8 were from Covance 
(Emeryville, CA). The anti-Lyn antibody, anti-Src, anti-a-tubulin antibodies and 
horseradish peroxidase conjugated secondary antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Mouse TNF-a ELISA kit was obtained from R&D 
Systems (Minneapolis, MN). Anti-phospho-tyrosine (4G10) antibody was from Upstate 
(Temecula, CA), HLA-DR Ab-1 (LN3) antibody was from Neomarkers (Fremont, CA) 
and anti-pLyn (396) antibody was purchased from Abeam (Cambridge, MA). Anti-CD68 
was obtained from Serotec (Raleigh, NC). Anti-APP antibody was purchased from 
Invitrogen (Camarillo, CA). The non-receptor tyrosine kinase inhibitor, dasatinib, was 
obtained from LC Laboratories (Woburn, MA). Elite Vectastain ABC avidin and biotin, 
biotinylated anti-rabbit, anti-mouse, anti-rat antibodies and the Vector VIP chromogen 
kits were from Vector Laboratories Inc. (Burlingame, CA). -\nti-PSD95 and anli-pSrc 
(1 yr 416) antibody was purchased from Cell Signaling Technology (Danvers, MA). Anti- 
synaptophysin and anti-pill tubulin antibodies were purchased from C-hemicon
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International, Inc (Temecula, CA, USA). The transgenic mouse line, strain 005864 
B6.Cg-Tg(APPswe,PSEN ldE9)85Dbo/J and wild-type mouse line, C57BL/6J were 
obtained from the Jackson Laboratory (Bar Habor, Maine).
Animal Use
All animal use was approved by compliance with the University of North Dakota 
Institutional Animal Care and Use Committee (UND IACUC). Mice were provided food 
and water ad libitum and housed in a 12 h light/dark cycle. The investigation conforms to 
the National Research Council of the National Academies Guide for the Care and Use of 
Laboratory Animals (8th edition).
Human Tissue
Human AD and age-matched control tissue was obtained from the 
University of Washington Alzheimer’s Disease Research Center, Grant # P50AG05136 
and University of Iowa Brain Bank. The investigation conforms to the principles outlined 
in the Declaration of Helsinki. All human tissue use was approved by the University of 
North Dakota Institutional Biosafety Committce/lnstitutional Review Board.
Preparation o f Peptides
A p t-42 was purchased from Bachem (Torrance, CA) or American Peptide 
(Sunnyvale, CA) for fibril and oligomer preparations, respectively. Api-42 pepliu. 
dissolved in 1:1 acetonitrile-water, aliquoted and dried. The aliquoted peptides were 
stored a t-20 degree C until use. For oligomer preparation, each tube was dissolved in 50 
pL HFIP and then diluted with 175 pL of sterile water and stirred at room temperature 
for 48h. The peptide was then spun at 14,000 rpm, for 10 min and the supernatant 
quantified using the method of Bradford (Bradford, 1976). For Ap fibril preparations.
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Api-42 peptide was dissolved in deionized water and incubated for a week at 37 degrees 
C. Before use, the fibril was mixed well and quantified using the Bradford assay.
Structural Peptide Analyses
For Western blot analysis of SDS-stable multimeric forms of oligomers, the 
peptide was diluted to different concentrations, separated by 15% SDS-PAGE and 
analyzed by Western blot using 6E10 (anti-AP) as the primary antibody. For dot-blot 
analyses of oligomers and fibrils, lpg each of Ap oligomer or fibril were dot blotted onto 
polyvinylidene fiouride (PVDF) membrane and incubated with A11 (anti-oligomer) and 
6E10 (anti-AP) antibodies and analyzed via enhanced chemiluminescence (GE 
Healthcare, Piscataway, NJ).
BV2 Cell Line
Immortalized murine microglial BV2 cells were obtain 1 from Dr. Gary E. 
Landreth, Cleveland, Ohio. The cells were amed at 3 x I0h cells/dish in 100-mm 
dishes in DMEM/FP fGibco RBL, Rockville, MD) supplemented with 10% heat- 
inactivated FBS (U.S. Biotechnologies Inc., Parkerford, PA). 5% horse serum (Equitech- 
Bio, Inc., Kerrville, TX), penicillin G (100 units/ml), streptomycin (100 mg/ral), and 1- 
glutamine (2 niM) and incubated at 37 °C in a humidified atmosphere containing 5% COt 
and 95% air.
Tissue Culture
Microglia cultures were derived from the brains of postnatal day 1-3 C57BL/6J 
mice (Floden and Combs, 2006). Briefly, cortices were removed and trypsinized. The 
trypsin was inactivated in microglial growth media (DMEM/F-12 with L-glutamine 
(Invitrogen) containing 10% heat-inactivated FBS, 5% heat-inactivated horse serum, and
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antibiotics, penicillin, streptomycin and neomycin (Gibco, Invitrogen). The tissue was 
triturated and plated into tissue culture flasks. After 24 hours all media and cellular debris 
was replaced with fresh media. After 7 more days one half of the media was replaced and 
cells were maintained as a mixed glia culture until day 14. At 14 days in vitro, microglia 
were shaken from the mixed glial culture at 200 rpm for 45 min and collected for use.
Cell Stimulation
BV2 cells and/or microglia were placed into serum-free DMEM/F12 media for 
stimulations with A|3 oligomers or fibrils. To inhibit tyrosine kinases, cells were 
pretreated with drug or vehicle (DMSO) for 30 min before adding the appropriate 
concentrations of peptides. For ELISA analysis, cells were stimulated in 96-well plates 
(20,000 cells/ well, 75 pL serum-free DMEM/F12) for 24 hours with 8 replicates per 
condition repeated 4-5 independent times. Experiments for Western blot analyses were 
performed for 5 minutes to assess signaling changes. After stimulation, cells were lysed 
in RIP A buffer (20mM Tris. pH 7.4, 150mM NaCl, ImM Na^VCE lOmM NaF, ImM 
EDTA, ImM EGTA, 0.2mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.1% 
SDS, and 0.5% deoxycholate) with protease inhibitors (AEBSF 104mM, Aprotinin 
0.08mM, Leupeptin 2.ImM, Bestatin 3.6mM, Pepstatin A 1.5mM, E-64mM). Protein 
concentrations were determined using the Bradford method (Bradford, 1976). For toxicity 
analyses, cells stimulated for 24 hours were used for MTT reduction toxicity assay.
Enzyme Linked-immuno-sorbent Assay (ELISA)
Media was collected from microglia following 24 hour stimulation for ELISA 
analysis. Levels of mouse TNF-a in the media were determined using commercially 
available ELISA kits according to the manufacturer’s protocol (R&D Systems).
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Cell Viability Assay
The MTT reduction assay was performed to assess changes in cell survival. In brief, 
the media was removed from cells stimulated with or without A|3 and dasatinib and 
replaced with media containing 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT, lOOpg/mL) for 4 hours. The media was aspirated and the reduced 
formazan precipitate was dissolved in isopropanol and absorbances read at 560/650nm 
via plate reader and averaged. For the Lactate Dehydrogenase Release (LDH) Assay, 
media was collected following 24 hour cell stimulation and centrifuged (14,000xg, 2 min, 
25°C). Aliquots were then added to a 96-well plate and LDH concentrations assayed 
according to manufacturer’s instructions (Promega Corporation, Madison, WI). 
Background absorbance was subtracted from each condition. Values were averaged (± 
SD).
Western Blot Analysis ofBV2 Cells and Microglia Cultures 
Cell lysates from 5 minute stimulations were resolved by SDS-PAGE and 
transferred to PVDF membranes. Western blots were blocked and incubated in anti- 
phospho-tyrosine (4G10), anti-pSrc (Tyr 416) and anti-pLyn (Tyr 396) as primary 
antibodies with a-tubulin, Src and Lyn antibodies as the respective loading controls.
Blots were washed followed by incubation with HRP-conjugated secondary antibodies 
and antibody binding was detected via enhanced chemiluminescence (GE Healthcare, 
Piscataway, NJ).
Intracerebroventricular Infusion o f  A p  1-42 Oligomers and Dasatinib 
A|3 oligomers with or without dasatinib were infused into the right ventricle of 
C57BL/6 female mouse brains at 12 months of age. Mice were anesthetized with sodium
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pentobarbital (Nembutal, 70mg/kg) and a scalp incision made for stereotaxic placement 
of the cannula. Blunt end dissection caudally from the base of the scalp incision were 
performed to generate a small subcutaneous pocket for placement of an Alzet (model 
1004, 0.25pL/hour delivery rate, Cupertino, CA) osmotic pump in the sub-scapular 
region. A cannula (Brain infusion kit, Alzet) was stereotaxically placed into the right 
lateral cerebral ventricle at coordinates —1.0 mm mediolateral and -0.5 mm 
anterioposterior from EiCgma: -1.5 mm dorsal-ventral from skull. The cannulae were 
connected to subscapularly placed miniosmotic pumps (Alzet, model 1004) delivering 
either A|3 oligomers (1.6pg/day) or vehicle (4mM Hepes, 250pg/mL human high density 
lipoprotein) with or without dasatinib (500ng/kg/day) for 14 days. At the end of the 
infusion period, mice were euthanized, brains perfused with PBS-CaCf> and rapidly 
collected. The right hemispheres were collected for cryosectioning and the left 
hemispheres were flash frozen in liquid nitrogen and lysed in RIPA buffer for 
biochemical analysis.
Collection o f  Brains from Different Age APP/PS1 Mice 
Brains from different aged APP/PS1 mice were collected for longitudinal 
analyses. 2, 4, 6 and 12 month old transgenic mice (n=5-6) along with their age-matched 
C57BL/6 wild type controls were euthanized and perfused with PBS-CaCB. Brains were 
rapidly dissected and divided into left and right hemispheres, with right hemispheres 
fixed in 4% paraformaldehyde for sectioning. The left hemispheres were further dissected 
into different brain regions to obtain hippocampus, temporal cortex, frontal cortex and 
cerebellum and flash frozen using liquid N2. The frozen tissue was lysed using RIPA with 
protease inhibitor and quantified by the method of Bradford.
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Subcutaneous Infusions o f Dasatinib into APP/PS1 mice 
Dasatinib was infused subcutaneously into female APP/PS1 mice at 13 months of 
age. Dasatinib was delivered via mini-osmotic pumps (model 1004. 0.25pL/hour delivery 
rate, Alzet, Cupertino, CA). Pumps delivered either vehicle (DMSO/Hepes) (n=6) or 
dasatinib (500ng/kg/day) (n=7) for 28 days. At the end of the infusion period, mice were 
euthanized, brains perfused with PBS-CaCh, and rapidly collected. The right 
hemispheres were collected for fixing in 4% paraformaldehyde and the left hemispheres 
were flash frozen in liquid nitrogen for biochemical analysis.
Immunostaining Mouse Brains
The paraformaldehyde fixed right hemispheres for different age mice or from 
dasatinib treated mice were sectioned using a freezing microtome. Briefly, 
paraformaldehyde fixed tissue was embedded in a 15% gelatin (in 0.1M phosphate 
buffer) matrix and immersed in a 4% paraformaldehyde solution for 2 days to harden the 
gelatin matrix. The blocks were then cryoprotected through 3 cycles of 30% sucrose for 
3-4 days each. The blocks were then flash frozen using dry-ice/isomethylpentane, and 
serial sections (40pm) were obtained using a freezing microtome. Serial sections were 
used for immunostaining with anti- pTyr (4G10) antibody at a dilution of 1:1000. anti-A(3 
(4G8) and anti-CD68 at a dilution of 1:500, anti-pSrc as 1:250. anti-GFAP antibody at a 
dilution of 1:1000, anti-Al 1 antibody at 1:250, O.C. antibody at 1:4000, and anti-111 
antibody at a dilution of 1:500 followed by incubation with biotinylated secondary 
antibodies (1:2000 dilution) (Vector laboratories Inc. Burlingame, CA) and avidin/biotin 
solution (Vector ABC kit). Immunoreactivity was visualized using visible light 
chromogens VIP, Vector Blue, and DAB (Vector Laboratories). The slides were
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dehydrated and cover slipped using VectaMount (Vector Laboratories) following a 
standard dehydrating procedure through a series of ethanol solutions and Histo-Clear 
(National Diagnostics, Atlanta, GA). Images were taken using an upright Leica DM1000 
microscope and Leica DF320 digital camera system. Figures were made using Adobe 
Photoshop 7.0 software. For quantitation purposes, 1.25X images were taken from 3 
consecutive serial sections, (960pm apart) throughout the hippocampal region. Optical 
densities from the temporal cortex and CA1 regions from the same serial sections were 
measured using Adobe 1 otoshop software (Adobe Systems, San Jose, CA). All sections 
were immunostained at the same time to minimize background variability and 
background values in an unstained area of tissue for each section was set to zero using the 
curve tool before measuring optical density values. The optical density of the entire 
temporal cortex region/CAl region from a representative section was selected via 
marquee. The same size marquee was applied to all sections across all conditions to allow 
comparison of optical densities independent of area changes. The values for each section 
were averaged (3sections/brain, 5-7 brains per condition) and plotted for A(3, 
immunoreactivity for dasatinib infusion animals and A|3 and CD68 immunoreactivities 
for longitudinal study animals. For quantitating phosphotyrosine immunostaining for 
different aged APP/PS1 and wild type mice, the serial sections were viewed under a 
microscope and the number of 4G10 positive plaques were counted from the entire CA1 
and temporal cortex regions for all the animals in each condition. The numbers of plaques 
were averaged (3 sections/brain, 5-7 brains per condition) and plotted.
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Double Label Immunofluorescence
For double label immunofluorescence staining, tissue was incubated in the desired 
primary antibodies and then corresponding Texas red and FITC-conjugated secondary 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Tissue was counterstained with 
DAPJ and visualized using a Zeiss LSM-510 META Confocal Microscope (Thornwood, 
NY).
Western Blot Analyses o f  Mouse Brains
Hippocampus and temporal cortex were removed from flash frozen brains of 
treated mice, lysed, sonicated in RIPA buffer, and quantitated using the Bradford method 
(Bradford, 1976). The lysates were resolved using a custom-built 28-well comb and 10% 
SDS-PAGE and transferred to polyvinylidene di fluoride membranes for Western blotting 
using anti-pTyr (4G10), anti-APP, anti-Aff (6E10), anti-GFAP, anti-TNF-a and anti- 
CD68 antibodies with a-tubulin as their loading control, anli-pSre (Tyr416), anti-pLyn 
(Tyr 396) antibodies with anti-Src and anti-Lyn as their respective loading controls and 
anti-PSD95 and anti-synaptophysin with pill-tubulin as the loading control. Antibody 
binding was detected using enhanced chemiluminescence. Western blots were quantified 
using Adobe Photoshop software. Optical density (O.D.) of bands were normalized 
against their respective loading controls and averaged (+/-SEM).
Thioflavin Staining
Mouse brain sections from Ap oligomer and vehicle infused animals were stained 
with thioflavin (O.lg/lOmL) and counterstained with 4,6-diamidino-2-phenylindole 
(DAPI) (Invitrogen) to visualize the nucleus. To quench lipofuscin autofluorescence, the
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sections were then incubated in 0.1% Sudan Black for 30 min, rinsed with PBS and cover 
slipped using PBS-glycerol ( 1 :1).
Human Tissue Double Staining
Human tissue was obtained from University of Washington Alzheimer 
Disease Research Center (ADRC, NIH P50AG05136) and was sectioned via freezing 
microtome (40pm) for immunostaining using DAB or Vector Red (Vector Laboratories, 
Burlingame, CA, US) as the first chromogen. The sections were then stripped using 0.2N 
HC1, 5 min. and incubated with the second primary antibody for immunostaining using 
Vector Blue or Vector SG (Vector Laboratories) as the second chromogen.
Dmaze
T-maze analysis was performed as described preciously (Wenk. 1998). Briefly, 
upon completion of the in vivo infusion period mice were placed into the starting arm. 
and the door was raised to allow animals to walk down the stem and choose an arm. Once 
the mice entered an arm with all four feet, they were returned to the starting arm and the 
door was closed. After 30 sec, the door was opened and the mice were allowed to choose 
an arm again. The process was repeated for 9 trials with a 30 sec interval between each 
trial. The choice of arms was noted each time and the number of alternations between 
trials for each mouse was averaged and plotted.
Dot Blot
To obtain a dose response curve for the LDDN drugs on BV2 cells, the cells were 
untreated (control), vehicle-treated, or treated with 0.0005 pM, 0.005 pM. 0.05 pM. 0.5 
pM, 5 pM and 50 pM of the drug for 30 minutes. The cells were then lysed in RIP A 
containing protease inhibitor and Bradford quantified. Lysates were diluted with 3X
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sample buffer, boiled, and stored in -20° for use. For dot blot analyses, PVDF membranes 
were prepared by first incubating in methanol solution for 5 minutes, and then soaking in 
Tris-Glycine solution for 10 minutes. The membranes were then placed into a dot blot 
apparatus and the apparatus was closed to create an air-tight seal for the vacuum to work. 
Using a narrow-mouth pipet, 2 microgram of lysate was blotted onto each well. After the 
loading was complete, the vacuum pump was turned on for 30sec-lmin, to make sure all 
the solution was pulled through the membrane allowing protein to adhere. The 
membranes were then blocked in 3%BSA solution and incubated in anti-pTyr (4G10), 
anti-pLyn, anti-pSrc and anti-pERK antibodies with u-tubulin, Lyn, Src and ERK2 
antibodies as loading controls overnight at 4°C. Blots were rinsed the next day and 
incubate in secondary antibodies and detected with enhanced chemiluminescence (GE 
Healthcare). Dot blots were quantified using Adobe Photoshop software. Optical 
densities of bands were normalized using appropriate loading controls and averaged (+/-) 
SD.
Statistical Analysis
Data are presented as mean +/— standard deviation. Values statistically different 
from controls were determined using one-way ANOVA. The Turkey-Kravner multiple 
comparisons post test was used to determine p values.
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CHAPTER 3
OLIGOMERIC Ap STIMULATES MICROGLIA THROUGH A TYROSINE KINASE
MECHANISM
Afi0 oligomer stimulated increased total protein phospho-tyrosine levels in primary 
microglia cultures that were attenuated by a non-receptor tyrosine kinase inhibitor,
dasatinib.
In order to characterize the form of A(3 oligomer used in our studies, we first 
performed a structural analyses of the prepared peptide. Preparations were separated via 
15% SDS-PAGE to demonstrate that the major detergent resistant multimer of Ap 
migrated with an apparent molecular weight loosely correlating with a trimeric/tetrameric 
form of the peptide that was stable even after incubation at 37 degree C (Fig. 5A). Larger 
amounts of loaded peptide demonstrated larger molecular weight multimers that were 
lesser species (Fig. 5A). This low molecular weight migration pattern correlates 
approximately with the multimeric confirmations of Ap oligomers isolated from human 
cerebral cortex as well as cerebrospinal fluid in which dimer/trimer forms o f Ap have 
been the primary forms observed (Klyubin et al.J 2008; Shankar et al., 2008; Villemagne 
et al., 2010; Shankar et al., 2011 ). This demonstrates that several detergent resistant 
species of oligomers are present in our preparation validating their use for subsequent 
cellular stimulations. In order to further confirm that the peptides were in a stable 
oligomeric conformation, dot blot analyses were performed after a period of 48h at 37 
degree C. Oligomeric peptides were compared to fibrillar peptide. As expected, both
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fibrils and oligomers were immunodetected with an anti-Ap antibody 6EI0 (Fig. 5B). 
However, only the oligomeric preparation was detected by the anti-oligomer antibody 




Figure 5. Structural characterization of A(H-42 oligomers (AfJ„) and Ap 2 fibrils 
(APf). The peptide (A) A()„ was prepared and stored overnight at 4 or 37 degree C to 
assess multimer stability. Increasing concentrations of peptide were separated by 15% 
SDS-PAGE and Western blotted with anti-Ap antibody, 6EI0. (B) Alternatively, 
prepared Apo and Apf were dot blotted ( I jig each) onto PVDF and incubated with anti-Ap 
antibody, 6E10. or anti-oligomer antibody. Al l .  Arrows indicate border between 
stacking and resolving gels for 6E10 Western blots.
We next determined the appropriate concentration of Apo for stimulating 
microglia. Our prior studies demonstrated that oligomeric peptide was sufficient to
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increase primary murine microglia total protein phospho-tyrosine levels although the 
concentrations employed were above the physiologic range and included a larger range of 
multimeric species in the preparation (Sondag et al., 2009). Primary murine microglia 
cultures were treated with varying concentrations of Aft,, for 5 minutes in order to assess 
the signaling response stimulated by peptide interaction. Oligomeric peptide stimulated 
an increase in total protein phospho-tyrosine levels (Fig. 6A) that was significantly 
different from controls even as low as lOOnM (Fig. 6B). Importantly this concentration is 
similar to that reported from human CSF and human cell culture conditioned medium 
(Seubert et al., 1992; Podlisny et al., 1995).
Because different proteins are recognized with anti-phospho-tyrosine antibodies, 
it is very common to see different overall Western blot banding patterns with different 
concentrations of ligands and different time courses of stimulation since protein 
phosphorylation/dephosphorylation is dynamically regulated during all o f the signaling 
events initiated during any acute stimulation. Indeed, as can be seen from Figure 6, some 
phospho-tyrosine immunoreactive bands steadily increase with dosage while others 
demonstrate a biphasic response. To further validate this point, we examined the changes 
of two specific tyrosine kinases in these experiments. The non-receptor tyrosine kinase. 
Src, was elevated in its active, phosphorylated form at lOOnM Ap0 stimulation, while 
there was no change in the levels of active, Lyn kinase levels with either of the Ap« doses 
(Fig.6B). Because of this complex dynamic change we focused on the concentration that 
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Figure 6. Oligomeric Apl-42 stimulated increased microglial protein phospho- 
tyrosine levels that were attenuated by the tyrosine kinase inhibitor, dasatinib. (A)
Primary microglia were vehicle treated (v), or stimulated for 5 min with 0.1 pM, 1 pM and 
5pM A(3„. Cell lysates were resolved by 10% SDS-PAGE and Western blotted using anii- 
phospho-Tyr (4G10), anti-pSrc, anti-pLyn antibodies or anti-a-tubulin, anti-Src and anti- 
Lyn (loading controls) antibodies. A Representative blot from 5 independent experiments 
is shown. (B) Densitometric analyses of the Western blots was performed normalizing 
protein phospho-tyrosine, pSrc and pLyn levels against their respective a-tubulin, Src and 
Lyn controls and averaging +/-SD. Percent fold changes in phospho-tyrosine levels were 
plotted (*p< 0.05 from vehicle). (C) Primary microglia were stimulated for 5 min with 
1 pM Ap0 or without 30 min pretreatment with 1 OOpM dasatinib (d). A 
representative Western blot from 3 independent experiments is shown. (D) Densitometrie 
analyses of Western blots were performed for protein phosphotyrosine levels normalized 
to their respective a-tubulin control (*p<0.05 from vehicle and dasatinib, **p<0.01 from 
AP+dasatinib).
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In order to determine whether this AP stimulated inc % ,e in protein phospho-tyrosine 
levels could be inhibited pharmacologically, a clinically relevant non-receptor tyrosine 
kinase Src/Abl inhibitor, dasatinib, was used to assess its ability to attenuate the oligomer 
stimulated change in total protein phospho-tyrosine levels (Shah et al., 2004; Das et al., 
2006) (Fig.6C). As expected, dasatinib pretreatment attenuated the Af3o stimulated 
increase in total protein phospho-tyrosine levels (Fig. 6D). This data indicates that Apo is 
able to stimulate increased tyrosine kinase activity in primary murine microglia at 
physiologically relevant concentrations and this can be attenuated through the use o f a 
non-receptor tyrosine kinase inhibitor, dasatinib.
Af}0 oligomer stimulated increased TNF-a secretion from primary microglia cultures 
To assess cell viability in the presence of oligomeric A|3 for microglia, primary 
microglia cultures were treated with different doses of Apo. The cells were then used for 
MTT assay to determine the toxicity levels. lOpM Apo proved to be toxic to the cells as 
compared to control and vehicle treated microglia (Fig 7A). In order to determine 
whether the increase in tyrosine kinase activity was responsible for a change in secretory 
phenotype, microglia were stimulated with AP oligomers and fibrils with or without 
increasing concentrations of dasatinib for 24 hours. A concentration of lpM  APo was 
used for the stimulations based upon the fact that a robust stimulatory change in protein 
phospho-tyrosine levels was observed with this concentration (Fig. 6A) as well as the 
toxicity data from MTT analyses o f microglia cells (Fig. 7A). Both fibrillar and 
oligomeric AP stimulated a significant increase in TNF-a secretion that was attenuated in
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a dose dependent fashion (Fig. 7B). Since dasatinib attenuated TNF-a secretion 
maximally at the lowest concentration employed, lOOpM, this suggests that the drug 
concentration curve employed was already above the IC50 (Johnson et al., 2005). This 
data demonstrated that oligomer Ap stimulated a proinflammatory cytokine secretory 
phenotype that was dependent upon propagation of the tyrosine-kinase based signaling 
response. The cell viability MTT reduction assay demonstrated that neither the peptide 
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*ure 7. Oligomeric A01-42 stimulated increased microglial secretion of the 
^inflammatory cytokine, TNF-a, that was attenuated by dasatinib. (A) Primary 
:voglia were untreated (control), vehicle treated, or stimulated with IpM and lOpM 
o for 24 hr to assess cell viability using the MTT assay. Absorbance values 
i0/650nm) were averaged+/-SD. (*p<0.05 from vehicle). (B) Primary microglia were 
stimulated (control), DMSO vehicle treated (v), or stimulated for 24 hours with 1 uM 
o or lOpM Apfin the presence/absence of lOOpM, InM and lOnM dasatinib. Media 
5 collected from treated cells and used to quantify changes in TNF-a secretion via 
ISA. Secreted values were averaged +/-SD (*p< 0.05 from control and vehicle). (C) 
er media removal, the treated cells were used to assess cell viability via the MTT 
uction assay. Absorbance values (560/650nm) were averaged+/-SD.
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A/i„ oligomers stimulated tyrosine kinase dependent microgliosis in vivo 
in order to validate the relevance of the in vitro findings, we next determined 
whether A(30 could stimulate a tyrosine kinase associated microgliosis in vivo. Aj30 was 
intracerebroventricularly infused into the right lateral ventricle of 12 month old C57BL/6 
mice for 14 days to stimulate gliosis in the absence or presence of co-administered 
dasatinib. Aff, infused animals demonstrated a robust increase in microglial-like 
phospho-tyrosine immunoreactivity that spatially correlated with increased reactive 
microglial CD68 immunoreactivity (Fig.SA). Densitometric analysis of the 
immunostaining demonstrated that dasatinib significantly attenuated the A|30-dependent 
increase in both phospho-tyrosine (Fig.SB) and CD68 (Fig. 8C) immunoreactivity. To 
validate the correlation between increased phosphotyrosine immunoreactivity and 
microgliosis, A|3(,-infused tissue was double labeled using anti-phosphotyrosine (4G10) 
antibody and CD68 antibody, along with control brain sections. CD68-positive microglia 
co-localized with phosphotyrosine immunoreactivity in the Af3-infused mouse brains 
(Fig. 8D).
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Figure 8. Intracerebroventrieular infusion of oligomeric Af}l-42 stimulated 
increased protein phospho-tyrosinc and CD68 imiminoreactivity that was 
attenuated by dasatinib. A[} oligomer (1.2mg/day) or vehicle control (human 11DL in 
artificial CSF) in the presence or absence of drug (500ng/kg/day) were infused into the 
right lateral ventricle of 12 month old male C57BI.6/J mice for 14 days (n 6). Brains
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were fixed, sectioned, and immunostained using anli-phospho-tyrosine (4G10) and CD68 
antibodies. (A) Representative images from the dentate gyrus of the rigiit hippocampus 
are shown. The arrow indicates the region imaged for the high magnification insets. 
Optical density (O.D.) of immunoreactivities for (B) phospho-tyrosine and (C) CD68 
were quantified from serial sections o f the CA1 region. (*p< 0.001 from c, v, dasatinib 
(das) and Ap+dasalinib). (D) Afi oligomer infused brains along with 12-month APP/PS1 
and control mouse brains were double-immunostained using anti-phospho-tyrosine, 4G10 
(red) and anti-CD68 (green) antibodies and counterstained with DAPI. Images shown are 
40x magnification.
In order to compare this acute model of Ap oligomer stimulated increase in 
protein phospho-tyrosine immunoreactivity to more chronic gliosis paradigms, 
microgliosis in infused brains was compared to that observed in a common transgenic 
mouse model of AD. This particular APP/PS1 model is a double transgenic line that 
expresses chimeric mouse/human amyloid precursor protein (Ms/Hu APPswe) and a 
mutant human presenilin 1 (PSldE9), allowing the mice to secrete human Ap peptide. 
This mouse model of AD shows a progressive increase in AP deposition with age 
(Garcia-Alloza et al., 2006). As expected. CD68 positive microglia in this model but not 
C57BL/6J controls correlated with increased phospho-tyrosine immunoreactivity (Fig. 
8D). This demonstrated that elevated phosphotyrosine immunoreactivity was a common 
presentation of reactive microglia across disease model paradigms including both acute 
and transgenic models.
However, it was not clear whether the phospho-tyrosine immunoreactive, 
activated microglia in the AP oligomer infused brains correlated with oligomeric AP
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deposition. In order to determine whether microgliosis in the infusion model correlated 
with oligomeric Af-i deposits, immunohistochemical analyses of Ap in infused brains was 
performed. Staining with the anti-AP antibody, 4G8, demonstrated immunoreactivity 
(Fig. 9A) broadly correlating with the same localization pattern of CD68 and phospho- 
tyrosine immunoreactivity observed in the peptide infused animals (Fig 8A). To 
determine whether the infused, immunodetected Apo had remained oligomeric rather 
than converting to fibrils, sections of treated brains were stained using anti-oligomer 
antibodies, A 11 and 111 to detect oligomeric species. Both A11 and 111 antibodies 
demonstrated positive immunoreactivity in the Apo infused brains compared to vehicle- 
infused and control animals (Fig. 9B). This was supported by the fact that Ap<, infused 
animals were negative for thiolhvin staining and comparable to the vehicle treated group, 
suggesting that the immunodetected AP in infused brains had not fibrillized (Fig. 9C). To 
further validate the use o f  anti-oligomer antibodies at recognizing non-ftbril 
confirmations in situ, again, the transgenic APP/PS1 model was used. Immunostaining of 
brains from 12 month old animals demonstrated robust immunoreactivity with anti-fibril 
antibody, OC, compared to control animals (Fig. 9D). However, abundant 
immunoreactivity of non-fibril, oligomeric Ap was also observed using Al l ,  anti­
oligomer antibody in these brains. Indeed, although OC and A 11 immunoreactivity co- 
localizcd to the same plaque structures, each antibody often displayed unique 
immunoreactivities within plaques (Fig. 9D). This not only indicates that plaques contain 
heterogeneous Ap conformations but also suggests that anti-oligomer antibodies are 
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Figure 9. Brains of Aji oligomer-infused animals were thioflavin negative hut 
displayed inuminoreactivity with anti-Ap, 4(i8, and anti-oligomer, A! 1 and I11 
antibodies. (A) Brains from wild-type control, vehicle-infused, and Aft oligomer-infused 
animals (+/-) dasatinib were immunostained with anli-Ap (4G8) antibody. Representative 
images from the dentate gyrus of the right hippocampus are shown. (B) Brains were also 
immunostained with anti-oligomer antibodies, A 11 and I I 1, to detect infused peptide.
Representative images of control, vehicle-infused, and A(3 oligomer-infused animals are
shown, (C) Brains from vehicle-infused and Ap oligomer- infused C57RL/6J mice were 
stained with thioflavin to identify the presence of any fibrils and counterstained with
DAP! as a nuclear stain and Sudan black to quench autofluorescence. Representative
images from the dentate gyrus are shown from 6 animals per group. (D) Brains from 12 
month old C57BL/6J control and APP/PS1 mice were immunostained with A11 and OC 
antibodies to visualize fibrillar and oligomeric AP peptide deposition. Representative
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double label with A 11 (brown) and OC (blue) is shown. Arrows indicate only A 11 
immunoreactivity (brown), only OC immunoreacitvity (blue) and co-localization (black).
AD brains demonstrated increased protein phospho-tyrosine, A [l and active Src kinase
levels compared to age matched controls 
To further establish the correlation between Ap oligomer levels and tyrosine 
kinase dependent microgliosis during disease, we compared human AD tissue with age 
matched non-demented controls. As seen in the in vitro and in vivo rodent data, 
examination of temporal cortex from human AD brains demonstrated a significant 
increase in overall protein phospho-tyrosine levels (Fig. 10A,B). This correlated with a 
significant increase is phosphorylated active forms o f the tyrosine kinase, Src, as well as 
Lyn kinase, in diseased brains versus their corresponding age- matched controls 
suggesting that the protein phospho-tyrosine changes could be related to increased 
activity o f the Src family of kinases (Fig. 10C,D). AD and control tissue lysates were also 
analyzed via Western Blot analyses to examine levels of multimeric forms of Ap 
oligomers. Densitometric analysis o f the multimeric SDS-stable species (Fig. 5A) 
demonstrated that AD brains had a significantly higher level than age-matched controls 
(Fig. 10A,B) correlating well with the changes in protein phospho-tyrosine, active Src 
and active Lyn levels.
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Figure 10. AD brains had elevated protein phospho-tyrosine, active phospho-Src 
and phospho-Lyn levels compared to age-matched controls. AD and age-matched 
control (c) temporal lobe lysates (n==6) were resolved by 10% SDS-PAGE and Western 
blotted using (A) anti phospho-Tyr (4G10), anti-Ap (6E10), anti-a-tubulin (loading 
control) antibodies, (C) anti-Lyn, anti-phospho-Lyn (Tyr396), anti-Src, and anti- 
phospho-Src antibodies. Optical density of (B) Total phospho-Tyr or A(3 multimers and 
(D) pLyn and pSrc from 6 AD and age-matched control brain blots were normalized to 
their respective a-tubulin blots or total protein Icve's (Lvn/Src) then averaged and 
graphed (+/-SD). (*p< 0.001)
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In order to verify whether the changes in protein phospho-tyrosine and AP 
oligomers correlated with microglial activation in the AD brains, immunostaining of 
fixed AD tissue was compared to age-matched controls. As expected, AD brains 
demonstrated defined, plaque-like deposits that were immunoreactive with the anti­
oligomer (A11) antibody (Fig. 11 A). Although A! 1 positive deposits were not uniformly 
associated with activated microglia there were clear instances o f HLA-DR (LN3) positive 
activated microglia directly associated with oligomeric deposits (Fig. 11A). This 
supported the in vitro (Fig. 7) and in vivo (Fig. 8) rodent observations of the ability of 
oligomeric Afi to stimulate microglia and suggested that a similar activation occurs 
during disease. To further support the rodent observations, the AD and control brain 
sections were immunostained to determine whether HLA-DR positive, reactive microglia 
demonstrated increased protein phospho-tyrosine levels indicative of increased tyrosine 
kinase activity. AD brains demonstrated increased immunostaining for reactive microglia 
compared to age-matched controls (Fig. 11B). More importantly, reactive HLA-DR 
positive microglia co-localized with anti-phospho-tyrosine immunoreactivity in both 
diffuse and clustered cell patterns supporting the idea that tyrosine kinase-dependent 












Figure 11. A population of AD brain microglia was phospho-tyrosine 
inimunoreactive and localized to Aji oligomers. AD and control (c) temporal lobe 
sections were immunostained using anti-HLA-DR antibody to identify microglia, anti­
oligomer antibody, A11, to visualize prefibril peptide, and anti-phospho-Tyr (4G10) 
antibodies. (A) A11/HLA-DR double label is shown with (i) only A 11 (red) 
immunoreactivity, (ii) double label (black arrow) and (iii) only HLA-DR (grey) 
immunoreactivity in the AD brain. (B) A double label for HLA-DR (brown)/phospho-Tyr 
(blue) is also shown. Images are representative of three cases each.
To begin identifying the specific enzymes responsible for the increased protein 
phospho-tyrosine levels, additional immunostaining of activated microglia in AD versus 
age-matched control brains was performed. Based upon the Western blot analysis of 
increased levels of active phosphorylated Src in AD brains (Fig. 10) immunostaining of 
active Src was again compared to the related family member, Lyn. Double label 
immunostaining using anti-HLA-DR to identify reactive microglia verified that a 
heterogeneous portion of the activated microglia also demonstrated increased 
phosphorylated, active Src immunoreactivity compared to age-matched control brains 
(Fig. 12 A). A small amount of reactive microglia in AD versus control brains also 
demonstrated immunoreactivity for phosphorylated active, Lyn (Fig. 12C). The 
immunostaining correlated well with the Western blot analysis changes (Fig. 10) and 
supported the idea that tyrosine kinase-dependent activation of microglia occurred in AD 
brains involving at least the non-receptor kinase, Src. Immunofluorescence and confocal 
imaging con firmed the colocalisation of reacti ve microglia (using HLA-DR antibody) 
and active Src immunoreactivity (Fig. 12B) as well as active Lyn immunoreactivity (Fig. 
12D)
HLA-DR positive microglia from AD brains displayed increased immunoreactivity fo r
active, phosphorylated Src and Lyn kinases.
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Figure 12. A population of AD brain microglia was immunoreactive for phospho- 
Lyn and phospho-Src. AD and control temporal lobe sections were immunostained 
using anti-HLA-DR antibody to identify microglia, anti-phospho-Lyn-396 antibody to 
identify activated Lyn kinase and anti-phospho-Src antibody to identify activated Src 
kinase. (A) p-Src (blue)/I ILA-DR (brown) double label and (C) p-Lyn (grey)ZHLA-DR 
(red) double label images are shown. Images are representative of three cases each. AD 
and control temporal lobe sections were also double-labeled using immunofluorescence 
using (11) anti-HLA-DR (green) and anti-pSrc (red) antibodies or (D) anti-HLA-DR 
(green) and anti-pLyn (red) antibodies.
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CHAFFER 4
ROLE OF SRC KINASE IN AMYLOID DEPENDENT MICROGLIOSIS IN AD 
Based upon our prior work demonstrating that both fibrillar and oligomeric Ap 
stimulate increased non-receptor tyrosine kinase activity in microglia (Sondag et al., 
2009), we determined whether a brain penetrant tyrosine kinase inhibitor, dasatinib, could 
attenuate activity of Src kinase in vitro.
The non-receptor tyrosine kinase inhibitor, dasatinib, decreased active-phospho Src
levels in microglia BV2 cells
In order to validate the Src-kinase inhibitory ability of dasatinib, the mouse 
microglia cell line, BV2, was treated with varying concentrations of dasatinib. Dasatinib 
is a small molecule ATP-competitive inhibitor of BCR/Abl and Src kinase with IC'50s for 
the isolated kinases of 0.55 and 3.0 nM, respectively (Lombardo et al., 2004; Nam et al., 
2005). FDA approved for use in cases of Chronic Phase Philadelphia chromosome­
positive Chronic Myelogenous Leukemia (CP-CML), dasatinib (Sprycel, Bristol-Myers 
Squibb), has been shown to the cross the blood brain barrier (Porkka et al., 2008). As 
expected, active, phosphorylated Src levels significantly decreased with increasing 
dasatinib concentrations from InM to 1 pM compared to vehicle treated BV2 cells 
(Fig. 13). For subsequent treatments of microglial cells in vitro, a dose o f lOOnM 
dasatinib was chosen to obtain an optimum effect of AP-dependent tyrosine kinase 
inhibition in primary cultures.
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Figure 13. Dasatinib dose-dependentiy attenuated active, phospho-Src kinase levels
in the BV2 cell line. (A) Microglial BV2 cells were vehicle treated (v), or treated with 
InM, 10nM, lOOnM and lpM dasatinib for 30 min. Cells lysates were resolved by SDS- 
PAGE and Western blotted using anti-phospho-Src, and Src antibodies. (B) 
Densitometric analyses of the Western blots were performed normalizing active-pSrc 
levels against their respective Src controls and averaging +/-SEM. Blots are 
representative of 6 independent experiments.
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murine microglia cultures
In order to determine whether dasatinib was able to reduce an Afi stimulated 
increase in active tyrosine kinase levels, primary microglia cultures were treated with A(3 
fibril with or without dasatinib. Microglial cells were pretreated with lOOnM dasatinib 
followed by 5 minute stimulation by 1 OpM Af3f to detect changes in the activated, 
phosphorylated forms of the specific non-receptor tyrosine kinases, Src and Lyn. As 
expected, Aft fibrils stimulated an increase in active-phospho S;c levels compared to 
vehicle treated cells (Fig. 14). The Ap-dependent increase in phospho-Src levels was 
significantly attenuated when cells where stimulated in the presence of dasatinib (Fig.
14). Although Aft fibrils did not significantly increase the levels o f active, 
phosphorylated Lyn kinase at the concentrations used, dasatinib was still able to 
significantly reduce levels of active phospho-Lyn indicating that the drug wes not 
specific to any particular Si family member (Fig 14). In addition, the data demonstrated 
that the Ap stimulated increase in microglial active Src kinase levels could be inhibited 
using a clinically relevant non-receptor tyrosine kinase Src/Ahl inhibitor, dasatinib.
Dasatinib attenuated the Aft-stimulated increase in active-phospho Src levels in primary
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Figure 14. Dasatinib attenuated an A|J-stiinulated increase in active, phospho-Src 
kinase levels in primary microglia cultures. (A) Primary microglia were vehicle treated 
(v,veh), or stimulated for 5 min with lOpM A(h in presence or absence of 30 min 
pretreatment o f lOOnM dasaunib. Ceils lysates were resolved by 10% SDS-PACiR and 
Western blotted using anti-pSrc or Src (loading control) antibodies and anti-pLyn or Lyn 
(loading control) antibodies. A Representative blot from 6 independent experiments is 
shown. (B) Densitometrie analyses o f the Western blots was performed normalizing 
active, phospho-Src levels against Src control and active, phospho-Lyn levels against Lyn 
control paid averaging +/-SE. Percent fold changes in phospho-Src levels were plotted. 
(*p<0.05 vs. vehicle, dasatinib. **p<0.01 vs. Ap+dasatinib for pSrc and *p<0.01 vs. A{1 
for pLyn)
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Dasatinib attenuated All-stimulated TNF-a secretion in primary microglia cultures 
In order to determine whether the AfKstimulated change in active Src levels was 
required for changes in phenotype, changes in secretion of the pro-inflammatory 
cytokine, TNF-a, was quantified from the primary microglia cultures in the presence or
absence o f dasatinib. Fibrillar A (I stimulated a significant increase in TNF-a secretion 
compared to control or vehicle treated microglia! cells (Fig. 15). This increase in TNF-a 
secretion was attenuated by lOOnM pretreatment of dasatinib with no effect on cellular 
viability (Fig. 15). The data demonstrated that inhibition of Src family kinase activity was
sufficient to prevent microglia from acquiring a reactive secretory phenotype upon AjJ
fibril stimulation in vitro.
tontfOi veh ♦ + * lOpM A|?
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Figure 15. Dasatinih attenuated A(51-42 stimulated-microglial secretion of the 
proinflanimatory cytokine, TNF-a. Primary microglia were unstimulated (control), 
DMSO vehicle treated (veh), or stimulated for 24 hours with lOpM Apr in the 
presenec/abscnce of lOOnM dasatinib. ( A) Media was collected from treated cells and 
used to quantify changes in TNF-a secretion via ELISA. Secreted values were averaged 
+/-SE. (It) After media removal, the treated cells were used to assess cell viability via the 
MTT reduction assay. Absorbance values (560/650ntn) were averaged+/-SE. (**p< 0.01 
from control, ***p<0.()01 vs veh.dasatinib and AjJ+dasatinib).
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An age-dependent increase in Aft plaque density correlated with microgliosis in a
transgenic mouse model o f  AD
To determine art appropriate age in vivo for examining increased tyrosine 
kinase activity and Aji-associated microgliosis, a transgenic APP/PSl mouse mode! of 
AD was used. Brains of varying aged APP/PSl mice were compared to age-matched 
controls to validate the use of this transgenic mouse model for our study. The APP/PSl 
mice were collected at 2 ,4 ,6  and 12 months of age along with their age-matched wild 
type (C57BL/6) mice and brains were sectioned for histology. Immunostaining 
demonstrated a significant increase in APP/PSl temporal cortex CD68 immunoreactivity 
in 6 and 12 month old mice compared to the earlier 2 and 4 month APP/PSl age groups 
m d  their age-matched C57BL/6 controls (Fig. 16). This increase correlated precisely 
with increased plaque-associated A{) immunoreactivity in the 6 and 12 month old 
APP/PSl mice (Fig. 16). Analyses of hippocampi from all groups showed similar results 
to the temporal cortex (data not shown). These data supported the notion that microglial 
activation in AD and its mouse models may be a consequence o f Ap fibril interaction. 
However, to validate an involvement o f tyrosine kinase act ivity in microglial phenotype 
changes during disease, APP/PSl brains were next immunostained with anti- 
phosphotyrosine antibody as an indirect m (hod to assess overall tyrosine kinase activity 
changes. Immunostaining mouse brains with anti - phosphoty rosine antibody. 4G10, 
demonstrated positive microglial-Iikc as well as neuronal-like immunoreactivity (Fig. 17). 
Counting plaque-associated 4G10 positive staining as putative microglia demonstrated a 
trend of age-associated increase in APP/PSl temporal cortex staining with a significant 
increase by 4 months o f age with significantly higher immunoreactivity at 6 and 12
months (Fig. i 7), Similar trends were observed in the hippocampus (data not shown). 
These data validated that by 12 months of age, this particular transgenic line had robust 
phosphotyrosine microglial reactivity in association with A{) plaques providing us with 
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Figure 16. Microgliosis in the APP/PS1 model of AD positively correlated with 
increased Aji plaque density. Serial coronal sections from 2 month, 4 month, 6 month 
and 12 months old control (C57BL/6) animals and age-matched transgenic animals 
(APP/PS1) (n*=6) were immunostained for (A) activated microglia (anti-C.D68) and Ap 
(anti-4G8 antibody) plaques. Representative hemi sections are shown with select high 
magnification panels. (8) Immunoreactivity densities from the temporal cortex region for 
0 )6 8  and 4G8 were quantified, averaged and graphed (+/-SE) *p< 0.001 from 2 and 4 
month APP/PS1 animals, "pO.OOl from 2, 4, 6 and 12 month wild type animals for 
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Figure 17. There was an age-dependant increase in total phospho-tymsinc immuno- 
positive plaques in a transgenic mouse model of AD (APP/PS1). (A) Serial coronal 
sections from 2 month, 4 month, 6 month and 12 months old control (C57BL/6) animals
and age-matched transgenic animals (APP/PS1) (n=6) were immunostained using
phospho-tyrosine antibody (4G10). (B) To omit the inclusion of neuronal 
phosphotyrosine staining, 4G10 positive plaques were counted from the temporal cortex 
and the hippocampus regions and averaged and graphed (+/-SE) *p<0.00l from 2 month 
APP/PS1 mice, #p<0.001 from 2 month and 4 months APP/PS1 animals, $p<0.001 from
2, 4 and 6 month APP/PS1 animals.
Dasatinib infusion decreasedphospho-Src but not phospho-Lyn levels in APP/PSI mice 
Based upon the temporal profiling of microgliosis we next determined whether 
inhibition of tyrosine kinase activity could attenuate the miciugiial reactivity in this line. 
Based upon our in vitro data we hypothesized that dasatinib treatment would attenuate 
the Ap-associated increase in tyrosine kinase activity, particularly Src, and subsequent 
inflammatory changes in the mice. In order to answer this question, 13 month old 
APP/PSI female mice were sub-cutaneously infused with dasatinib for 28 days. Dasatinib 
infusion significantly decreased protein phosphotyrosine levels in the hippocampus but 
not the temporal cortex compared to vehicle infused control animals (Fig. 18). More 
importantly, dasatinib infusion significantly decreased levels of active, phospho-Src in 
both temporal cortex and hippocampus compared to vehicle treated mice (Fig. 18). 
However, dasatinib infusion had no effect on the active, phosphorylated levels of the 
related Si unity member, Lyn kinase, demonstrating some specificity of the drug (Fig. 
18). These data demonstrated that a subcutaneous route of dasatinib delivery was able to 
inhibit levels o f active Src in the brains of the APP/PS1 mice.
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Figure 18. Dasatinib infusion reduced protein phosphotyrosinc and active phospho- 
Src kinase levels in APP/PS1 brains in vivo. Vehicle or dasatinib (500ng/kg/day) was 
infused sub-cutaneously into 13-month old APP/PS1 for 28 days (n=7). Hippocampus 
and temporal cortex regions were dissected from the left hemispheres and flash frozen for 
protein analyses. The frozen tissue was lysed in RIPA with protease inhibitor. (A) 
Hippocampal and (B) temporal cortex brain lysates from control (13 month APP/PS1 j, 
vehicle infused, and dasatinib infused animals were used for Western blot analyses using 
pTyr (4G10), pSrc, pLyn, a-tubulin, Src, and Lyn antibodies. (C) Optical densities were 
averaged and graphed (+/-SEM) for hippocampus *p< 0.05, ***p< 0.001 from control 
and for (D) temporal cortex *p<0.05 from control.
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Dasatinib infusion decreased TNF-a levels and microgliosis in APP/PSI mice 
Based upon the encouraging findings that dasatinib was able to exert brain effects 
and inhibit active Src levels we expected that dasatinib infusion should also attenuate 
microgliosis and TNFa secretion as observed in our in vitro findings. Dasatinib infusion 
significantly decreased TNFa levels in both the hippocampus and temporal cortex 
correlating with the decrease in active Src levels and demonstrating a clear brain anti­
inflammatory effect of the drug (Fig. !9). Moreover, levels of CD68, the reactive 
microglial marker protein, were significantly decreased in the hippocampus of dasatinib 
infused brains but not the temporal cortex. This data demonstrated that dasatinib 
inhibition of brain active Src levels correlates with a significant anti-inflammatory, 
microglial-inhibitory effect in APP/PSI mice. Interestingly, these effects appeared most 
robust in the hippocampus compared to the temporal cortex (Fig. 18,19).
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Figure 19. Dasatinib infusion reduced CD68 and TNF-a protein levels in 
hippocampus of 13 month old APP/PS1 brains in vivo. (A) Hippocampal and (B) 
temporal cortex brain lysates from control (n=7), vehicle (n=6), and dasatinib infused 
animals (n=7) were used for Western blot analyses for activated microglia (using CD68 
antibody) and pro-inflammatory cytokine TNF-a (anti-TNF-a antibody) antibodies with 
a-tubulin as the loading control. (C) Optical densities were averaged and graphed (+/- 
SEM) for hippocampus **p< 0.01 from controls and (D) temporal cortex *p<0.05 from
controls.
Dasatinih infusion did not alter APP, A ft, or synaptic protein levels in APP/PSI mice 
T '"'.amine the breadth o f changes that might result from dasatinih infusion we 
also determined whether adverse effects on neurons, astrocytes, or Aft deposition resulted 
from drug treatment in addition to the anti-inflammatory, microglial-inhibitory changes. 
However, dasatinih administration had no effect on either total APP levels or Aff levels in 
the hippocampus or temporal cortex of treated mice compared to vehicle controls (Fig. 
20). In addition, dasatinih treatments did not increase levels of the reactive astrocyte 
marker protein, GFAP, in the infused animals compared to vehicle control mice (Fig. 8). 
Finally, dasatinih treatment did not have any significant effects on levels of either 
presynaptic (synaptophysin) or post-synaptic (PSD 95) proteins in either the temporal 
cortex or hippocampus compared to vehicle treated mice (Fig. 20). These data 
demonstrated that the Src inhibitory, anti-inflammatory, microglia-inhibitory effects of 
dasatinih treatment did not correlate with any adverse effects such as increased 
astrogliosis, neuron or synaptic loss, and increased Aj3 deposition.
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Figure lO.Dasatinib infusion did not alter levels of AFP, Ajl, synaptic markers, 
synaptophysin, PSD95, or GFAP in hippocampus of 13 month old APP/PSI brains 
in vivo. (A) Hippocampal and (B) temporal cortex brain lysates front control (n-7), 
vehicle (n=6), and dasatinib (n=7) infused animals were used for Western blot analyses
using anti-AP clone 6E10 antibody, anti-APP, anli-synaptophysin, anti~PSD95 and anti-
GFAP antibodies. (C) Optical densities were averaged, and graphed (+/-SEM) for 
hippocampus and (D) temporal cortex.
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Da,natinib infusion decreased immunoreactivUy fo r  protein pkosphotyrosine, phospho-Src
and CD68 in APP/PSI mice
I o provide qualitative assessments along with the quantitative Western blot 
analyses, inimunohistochcmical studies were also performed from the treated animals. As 
expected, protein phosphotyrosine immunoreactivity in dasatinib infused mouse brains 
appeared dramatically less then vehicle treated mice in both the hippocampi ' and 
temporal cortex (Fig. 21). A similar trend of decreased immunoreactivity was observed 
for active phospho-Src in dasatinib treated animals versus vehicle control? (Fig. 21). 
Importantly, the decrease in immunoreactivity was observed in plaque-associated 
microglial-like cells demonstrating that the significant decreases in active Src and 
phosphotyrosine levels observed by Western blot analyses were a reflection o f microglial 
changes due to the drug. Also as predicted, levels o f CD68 reactive microglial 
immunoreactivity in dasatinib infused mice was noticeably decreased compared to 
vehicle treated mice in both the hippocampus and temporal cortex (Fig. 21). Consistent 
with the Western blot analysis, GFAP immunoreactivity for reactive astrocytes was not 
visually different between dasatinib and vehicle infused mice in either temporal cortex or 
hippocampus (Fig. 21). The qualitative immunostaining findings corroborated the 
quantitative Western blot analyses and validated that the significant decreases in pSrc 














Figure 21. Dasatinih infusion attenuated microgliosis, protein phospho-tyresine 
levels and active phospho-Src levels but not GFAP immunoreactfvity in I lit 
APP/PS1 model of AD. Right hemispheres from brains of dasatinih infused, vehicle 
infused and 13 month old APP/PS1 controls animals were fixed, sectioned and 
immunostained using anti-phosphotyrosine (4G10) antibody, CD68 antibody, and active. 
phospho-Src (anti-pSre) antibody. Representative 10X sections from the CA1 region of 
the hippocampus are shown with select high magnification fields.
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Aft plaque load was not affected by dasatinib infusions into the APP/PSJ mice 
One possible consequence o f attenuated tyrosine kinase activity in microglia 
could be inhibition o f phagocytic ability. It is well known, for instance, that tyrosine 
kinase activity can affect macrophage phagocytic ability (Greenberg et al., 1996; Aderem 
and Underhill. 1999; Fitzer-Altas et al., 2000). Therefore, inhibition of Src or related 
kinase activity might attenuate any ability microglia have to clear AJ5 deposits in the brain 
producing an unwanted side-effect of increased plaque load. Based upon the Western blot 
analysis dasatinib treatment had no effect on altering APP or Apt levels in the brains of 
mice (Fig. 21). However, to better assess whether the drug had any effects on insoluble 
fibrillar deposits in the brain, quantitative immunostaining of A|3 plaques was performed. 
Dasatinib treatment had no effect on plaque load in treated mice compared to vehicle 
controls in either the hippocampus or temporal cortex (Fig. 22). These data demonstrate 
that the microglial-inhibitory effects of dasatinib do not result in unwanted effects of 
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Figure 22. Dasatinib infusion did not change the Aft plaque toad in the brain of 
APP/PS1 mice. Serial sections from right hemishperes of brains of dasatinib infused,
vehicle infused and 13 month old APP/PS1 mice were immunostained using anti-Afi
antibody, clone 4ti8. and quantified for plaque load. ( A) Representative 1.25X sections 
of the brain hemipsheres are shown with select high magnification fields. (B) Optical
density measurements from the CA1 region o f hippocampus and temporal cortex regions
are shown +/- ST..
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Dasatinib infusion improved T maze performance in APP/PS1 mice 
Although there was no effect of dasatinib treatment on AfS deposition, the clear 
and somewhat specific effect of Src inhibition correlating with anti-inflammatory and 
microglial-inhibitor)' effects provided an opportunity to assess whether dasatinib could 
also provide cognitive improvement to the mice. After treatments, spontaneous 
alternations from dasatinib treated, vehicle treated, and control animals were quantified 
during 1' maze analyses. This particular model of spatial memory was selected based 
upon its sensitivity of detection o f cognitive deficit in AD mouse models (Stewart et ah, 
2011) and its preference for detecting changes in hippocampal-based performance 
differences (Duncan and Duncan, 1971; Loesche and Steward, 1977) since our most 
significant effects of drug were observed in hippocampus. Dasatinib infused animals 
demonstrated improved cognitive performance represented by a significant increase in 
spontaneous alternations compared to vehicle treated mice (Fig. 23). These data validated 
that subcutaneous administration o f the Src/Abl tyrosine kinase inhibitor, dasatinib, is 
able to provide cognitive enhancing effects to APP/PS1 mice while attenuating microglial 





Figure 23. Dasatinib infused APP/PS1 iniec demonstrated increased spontaneous 
alternations during T maze testing. Dasatinib or vehicle DMSO was infused sub­
cutaneously via min-osmotic pump into 13-month old APP/PS1 mice (n -7 , for 28-days. 
T-maze performance and numbers of spontaneous arm entry alternations was assessed on 




CHARACTERIZATION OF NOVEL SRC FAMILY KINASE INHIBITORS 
Although dasalinib exerted anti-inflammatory effects in vivo correlating with 
decreased levels of active Src, it had no effect on active Lyn. Based upon the data that 
increased active pLyn levels were observed in AD brains, Lyn kinase still represents a 
valid microglial inhibitory target in AD. In order to identify a Lyn selective inhibitor, a 
high throughput screening in vitro and kinase assay was performed screening over 20,000 
compounds. Four novel compounds were chosen to be characterized in cellular assays for 
their ability to inhibit two target kinases, Src and Lyn. The murine BV2 microglial cell 
line and primary microglial cultures were selected as the screening cells. These novel 
drugs, LDDN-00^3499, LDDN-0075935, LDDN-0125694 and LDDN-0127164, were 
used to treat microglial BV2 cells to determine their ability to decrease basal total protein 
phosphotyrosine levels as well as active, phosphorylated forms of Src. Lyn and ERK 
kinases. Of the four drugs, LDDN-0003499 dose-dependently inhibited active, 
phosphorylated Lyn kinase levels. To determine whether the drug could attenuate 
stimulated kinase activity, A[3 and LPS stimulated primary microglia cultures were 
treated with LDDN-0003499 to assess effects on active levels of Src and Lyn. This study 
characterized the ability of LDDN-0003499 to attenuate microgliosis via particularly 
Lyn inhibition in vitro. Further work is required to modify this compound for in vivo
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testing to determine whether it ean attenuate microgliosis and Lyn activity in an AD 
mouse model.
Assessment o f  LDDN drugs effects on viability 
Before screening drugs for any ability to alter cellular kinase activities, we first 
determined whether the drugs were toxic or not. Microglial BV2 cells were treated with 
LDDN-0003499, LDDN-0075935, LDDN-0125694 and LDDN-0127164 with increasing 
concentrations ranging from 0.5nM up to 50 pM for 24h. The media was removed and 
used for LDH release assays to determine cell viability. Quantitation o f LDH released 
from the media following drug treatment demonstrated that none of the four drugs were 
toxic at any of the concentrations used for treatment (Fig. 24). For subsequent 
experiments to assess effects on tyrosine kinase inhibition, 0.5nM, 5nM, 50nM, 0.5pM, 
5pM and 50pM concentrations were chosen for treatment of BV2 cells line as w'ell as 
primary microglia cultures.
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Figure 24. LDDN drugs were not toxic to microglial BV2 cells. Microglial BV2 cells 
were untreated (control), vehicle treated, or treated with 0.5nM, 5nM. 50nM, 0.5 pM, 
5pM and 50 pM (A) LDDN-000.,499, (B) LDDN-0075935, (C) LDDN-0125694 and (D) 
LDDN-0127164 for 24h. Media was removed and used for an LDM release assay to 
determine cell viability. 3 independent experiments with 8 replicates each were 
performed and absorbance values graphed and averaged +/- SO.
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LDDN-0003499 decreased total protein phosphotyrosine level in microglia BV2 cells 
In order to validate a tyrosine kinase inhibitory ability of the drugs in cells, the 
mouse microglia cell line, RV2, was treated with increasing concentrations o f LDDN- 
0003499, LDDN-0075935, LDDN-0125694 and LDDN-0127164. Of the four drugs 
analyzed using dot blot analyses, 50pM LDDN-0003499 was able to significantly 
decrease the levels of total protein phosphotyrosine in these cells as compared to vehicle 
treated cells (Fig. 25). LDDN-0075935, LDDN-0125694 and LDDN-0127164 were not 
able to inhibit protein phosphotyrosine levels at the concentrations used. The cell lysates 
were also analyzed using Western blot analysis to completely resolve the protein 
phospho-tyrosine profile. A dose-dependent inhibition of overall protein phosphotyrosine 
levels was observed with LDDN-0003499 whereas the other 3 drugs failed to show any 
inhibitory effects in these cells.
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Figure 25. LDDN-0003499 attenuated total protein phosphotyrosinc levels in the 
microglial IW2 cell line. Microglial BV2 cells were vehicle treated or treated with
i. 0.5 |.iM, 5pM and 50 pM (A) LDDN-0003499, (B) LDDN-0075935,
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(C) LDDN-0125694 and (D) LDDN-127164 for 24h. Cells lysates were used for dot-blot
analyses using anti-phosphotyrosine (4G10) antibody with a-tubulin as the loading 
control. Optical densities were graphed and averaged +/- SD (*p<0.05 vs. control and 
vehicle). (E) Cell lysates were resolved via SDS-PAGE and Western blotted using anti- 
pTyr and a-tubulin (loading control) antibodies. A representative Western blot is shown.
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LDDN-0003499 dose-dependent ly attenuated levels o f  active, phosphorylated Lyn in BV2
cells.
Although the drugs were tested for an ability to decrease total protein 
phosphotyrosine levels, the in vitro kinase assay target for these drugs was Lyn kinase. 
Therefore, in order to validate a cellular Lyn inhibitory ability of these drugs, BV2 cells 
were treated with increasing concentrations o f LDDN-0003499, LDDN-0075935, 
LDDN-0125694 and LDDN-0127164 for 24h. Cell lysates were analyzed using dot blot 
analyses for pSrc, pLyn and pERK levels. Quantitation of the blots demonstrated a dose- 
dependent decrease in active, phosphorylated Lyn kinase levels in the cells treated with 
LDDN-0003499 (Fig. 26). LDDN-0075935 and LDDN-0127164 were not able to 
attenuate or affect pLyn levels in the cells at any of the doses (Fig. 27-29). LDDN- 
0125169 inhibited pLyn at a number o f doses, as compared to vehicle treated cells, but 
this response was not dose dependent. LDDN-0003499 was also able to significantly 
reduce pSrc levels in these cells, although the response was not dose dependent. LDDN- 
0075935 and LDDN-0127164, again did not affect any change in pSrc levels. LDDN- 
0125169 was able to inhibit pSrc at a lower dose o f 0.5nM only, as compared to vehicle 
treated cells. As an unrelated kinase control, each drug was tested for ability to alter 
active levels o f the Ser/Thr kinase extracellular signal regulated kinase 2 (ERK2). There 
were no changes in active, phosphorylated ERK kinase levels in BV2 cells with treatment 
of any of the four drugs at the concentrat ions used. Western blot analysis of the 
microglial BV2 cells treated with LDDN-3499 revealed a dose-dependent attenuation in 
pLyn levels, but not pSrc levels. The other three drugs failed to affect any changes in 
acti ve levels of Src, Lyn or ERK kinases.
77
This data suggests that LDDN-0003499 may be a promising drug for specifically
inhibiting active pLyn levels in a dose dependant manner in microglia. To assess the
specific kinase inhibition on microgliosis, SOpM of LDDN-0003499 was chosen to 
obtain a maximal inhibitory e f  ect on tyrosine kinases in stimulated primary microglia 
cultures.
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Figure 26. LDDN-0G03499 dose-dcpendcntly attenuated active, phosphorylated Lyn 
levels in BV2 cells. Microglial RV2 cells were vehicle treated, or treated with 0.5nM. 
5nM, 50nM, 0.5 pM, 5pM and 50 pM LDDN-0003499 for 24h. Cells lysate*- 
for dot-blot analyses with anti-pSre n \  r -l ie,? (A), anti-pLyn (Tyr 396) (B) and anti- 
,u .RK (C) antibodies with Src, Lyn and ERK2 antibodies as their respective loading 
controls. Optical densities were graphed and averaged +/- SD (*p<0.05, **p<0.0l vs. 
control and vehicle). (D) Cell lysates were resolved via SDS-PAGE and western blotted 
using anti-pSrc, anti-pLyn, anti-pERK, anti-c-Src, anti-Lyn and anti-ERK2 antibodies. A 
representative Western blot is shown.
79
Figure 27. LDDN-0075935 did not attenuate active, phosphorylated Src, Lyn, or 
ERK levels in BV2 cells. Microglial BV2 cells were vehicle treated, or treated with 
0.5nM, 5nM, 50nM, 0.5 pM, 5pM and 50 pM LDDN-0075935 for 24h. Cells lysates 
were used for dot-blot analyses with anti-pSrc (Tyr416) (A), anti-pLyn (Tyr 396) (B) 
and anti-pERK (C) antibodies with Src, Lyn and ERK2 antibodies as their respective 
loading controls. Optical densities were graphed and averaged +/- SD. (D) Cell lysates 
were resolved via SDS-PAGE and Western blotted using anti-pSrc, anti-pLyn, anti- 
pIvRK. anli-c-Src. anti-Lyn and anti-ERK2 antibodies. A representative Western blot is 
shown.
SO
1.2 5 0.7 ,
pSrc pLyn
Figure 28. LDDN-0125694 did not dose dependency attenuate active, 
phosphorylated Src, Lyn, or ERK levels in RV2 cells. Microglial BV2 cells were 
vehicle treated, or treated with 0.5nM, 5nM, 50nM, 0.5 pM, 5pM and 50 pM LDDN- 
0075935 for 24h. Cells lysates were used for dot-blot analyses with anti-pSre (Tyr 416) 
(A), anti-pLyn (Tyr 396) (B) and anti-pERK (C) antibodies with Src. Lyn and ERK2 
antibodies as their respective loading controls. Optical densities were graphed and 
averaged +/- SD. (I)) Cell lysates were resolved via SDS-PAGE and Western blotted 
using anti-pSrc, anti-pLyn, anti-pERK, anti-c-Src, anti-Lyn and anti-ERK2 antibodies. A 
representative Western blot is shown.
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Figure 29. LDDN-0127164 did not attenuate active, phosphorylated Src, Lyn or
ERK levels in BV2 cells. Microglial BV2 cells were vehicle treated, or treated with
0.5nM, 5nM, 50nM. 0.5 pM, 5pM and 50 liM LDDN-0075935 for 24h. Cells lysates 
were used for dot-blot analyses with anti-pSrc (Tyr 4 16) (A). anti-pLyn (Tyr 396) (B) 
and anti-pERK (C) antibodies with Src, Lyn and ERK2 antibodies as their respective 
loading controls. Optical densities were graphed and averaged +/- SD. (D) Cell lysates
were resolved via SDS-PAGE and Western blotted using anti-pSrc, anti-pLyn, anti­
pERK, anti-c-Src, anti-Lyn and anti-ERK.2 antibodies. A representative Western blot is 
shown.
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Based on our earlier data and other work, it has been very well established that 
fibrillar Af3 and LPS can act as pro-inflammatory stimuli for microglia in the brain. 
However the primary rationale for this drug discovery effort was to identify small 
molecule capable of decreasing Ap stimulation of microglia. To assess the ability of 
LDDN-0003499 to decrease Ap or LPS stimulated tyrosine kinase changes in primary 
microglia cultures, cells were first stimulated with increasing concentrations of Apf and 
LPS to determine a concentration with adequate changes in increased active Lyn levels. 
As expected there was a dose dependent increase in total protein phosphotyrosine levels 
observed with Ap treatment of the microglia (Fig.30). Ap also stimulated increase in 
active, phosphorylated form of Src and Lyn kinases. Upon pretreatment on primary 
microglia cultures with 50pM LDDN-0003499, the Ap stimulated increase in pLyn and 
pSrc levels was attenuated, as compared to vehicle treated cells.
LDDN-0003499 attenuated an Afi dependent increase in active phosphorylated Src and
Lyn kinases levels in primary microglia cultures.
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Figure 30. LDDN-0003499 attenuated an AP-dependent increase in active, 
phosphorylated Src and Lyn levels in prim ary microglia cultures. (A) Primary 
microglia cultures were untreated, vehicle treated (v) or treated with 5 pM, lOpM, 20 liM 
A (3 or 25ng/ml LPS for 5 minutes. Cell lysates were resolved by SDS-PAGE for anti- 
pTyr (4G10), anti-pSrc, anti-Lyn, anti-pERK, anti-Src, anti-I,yn, anti-ERK and anti-cc-
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tubulin antibodies. Representative Western blots are shown. Primary microglia cultures 
were vehicle treated (v) or treated with 10 pM Ap in presence and absence of 50 pM 
LDDN-0003499. (B) Cell lysates were resolved by SDS-PAGE and blotted using anti- 
pSrc and anti-pLyn antibodies with Src and Lyn as loading controls. (C) Optical densities 
were averaged and graphed +/- SD (*p<0.05, **p<0.01 vs. AP treated cells)
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TNF-a, in primary microglia cultures.
In order to determine whether the LPS-stimulated change in increased active 
tyrosine kinase levels was required for changes in phenotype, increased secretion of the 
pro-inflammatory cytokine, TNF-a. was quantified from the primary microglia cultures 
in the presence or absence of LDDN-0003499. LPS stimulated a significant increase in 
TNF-a secretion compared to control or vehicle treated microglial cells (Fig. 31). This 
increase in TNF-a secretion was attenuated by pretreatment with 50pM drug with no 
effect of cellular viability (Fig. 31). The data demonstrated that inhibition of Src family 
kinase activity was sufficient to prevent microglia from acquiring are reactive secretory 
phenotype upon pro-inflammatory stimulation in vitro.
LDDN-0003499 attenuated LPS-mediated secretion o f the pro-inflammatory cytokine,
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Figure 31. LBDN-0003499 attenuated LPS stimulated-microglial secretion of the 
proinflammatory cytokine, TNF-a. Primary microglia were unstimulated (control), 
DMSO vehicle treated (v), treated with 0.5 uM. 5uM and 50 uM LDDN-0003499 or 
stimulated for 24 hours with 25ng/ml LPS in the presence/absence of the 50 pM LDDN- 
0003499 drug. (A) Media was collected from the treated cells and used to quantify
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changes in TNF-a secretion via ELISA. Secreted values were averaged +/-SD (*p< 0.05). 
(B) Media from treated cells was also used for to „ ssess cell viability via the LDH release 




This work demonstrates that AP oligomers and fibrils stimulate microglial 
activation in vitro via a tyrosine kinase associated pathway that results in increased 
secretion of the proinflammatory cytokine, TNF-u. It is possible to attenuate the 
oligomer-stimulated microglial phenotype change using a non-receptor tyrosine kinase 
inhibitor, dasatinib. The in vitro observations of oligomeric stimulation of microglia were 
validated in vivo demonstrating that intracerebroventricular infusion of oligomeric Ap 
also stimulated increased microgliosis via a tyrosine kinase-dependent mechanism that 
was attenuated by co-delivery of dasatinib. Finally, the rodent findings correlated with a 
reactive microglial increase in protein phospho-tyrosine, p-Lyn and p-Src levels in AD 
brains compared to controls. Since total protein phosphotyrosine, more specifically 
active, phosphorylated Lyn and Src kinase are associated with plaques as well as distinct 
microglia in AD brains, role of fibrillar Ap in activation of microglia phenotype cannot 
be ruled out. Collectively, all this data suggests that amyloid dependent microgliosis 
occurs through a tyrosine kinase dependent pathway. This mechanism of activation could 
prove to be very important therapeutically for attenuating pro-inflammatory microglial 
activation. In order to further understand the signaling pathway involved in amyloid 
based microglial activation, for pharmacological intervention purposes, a transgenic 
mouse model of AD, APP/PS1 mice, were also studied to assess protein phosphotyrosine 
changes with age. An age-dependent increase in plaque deposition in APP/PS1 mice
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correlated with increased phosphotyrosine immunoreactivity and microgliosis in these 
mice. In order to assess whether inhibition of tyrosine kinases attenuated pro- 
inflammatory changes, dasatinib was subcutaneously infused into aged (13 month) old 
APP/PS1 mice with established plaques and reactive microglia. The infusions 
demonstrated that dasatinib attenuated overall tyrosine phosphorylation and active Src 
levels, in particular, in the hippocampus. The drug did not affect A|3 plaque load but 
reduced microgliosis and TNF-a levels in these animals without affecting other cell 
types, neurons and astrocytes. Moreover, dasatinib provided a significant increase in 
cognitive performance in correlation with this anti-inflammatory action. Collectively, 
these findings support the idea that A(3 fibrils and oligomers can serve as a microglial 
activating ligand in disease contributing to their proinflammatory phenotype and use of 
selective non-receptor tyrosine kinase inhibitors is an effective strategy to limit 
microglial-mediated changes during disease (Fig. 32).
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Figure 32: Amyloid dependent microgliosis occurs through a Src kinase activation 
pathway
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Although it has been suggested that A|3-stimulated microglial activation 
contributes to the pathophysiology of AD (Banati et al., 1993; Del Bo el al., 1995; 
Giulian et al., 1995; Klegeris et al.. 1997; Combs et al., 2000; Combs et al., 2001a; 
Combs et al., 2001b; Floden and Combs, 2006) and a broad range of microglial secreted 
inflammatory markers are elevated in AD brains, including IL-la, IL-lp, TGF-p and 
TNF-a (Akiyama et al., 2000; Jara et al., 2007), enthusiasm for an anti-inflammatory 
approach to treating AD has decreased, in part, due to lack of drug efficacy of a number 
of human trials that targeted cyclooxygenase (Cox) activity in AD patients (Rogers et al., 
1993; Scharf et al., 1999; Aisen et al., 2002; Aisen et al., 2003; Thai et al., 2005). Indeed, 
Cox inhibition during later stages of disease had adverse effects and c fry demonstrated 
protection when administered long-term to asymptomatic individuals (Breitner et al.,
2011). One possibility for the lack of efficacy of Cox inhibitors could be because Cox 
enzymes are expressed by multiple cell types in the brain and general drug inhibition has 
no cellular selectivity. Another possibility for the failed efficacy is that Cox 1 or 2 
enzyme activities are simply not relevant targets for attenuating microglia-dependent 
changes. For this reason the direct signaling response initiated in microglia upon Ap 
oligomer and fibril stimulation was the focus of this study, ft has been reported from both 
AD brains (Tillotson and Wood, 1989a, b; Karp et al., 1994) and mouse models 
(Frautschy et al., 1998; Combs, 2009) that elevated protein phosphotyrosine levels are 
reliable markers of reactive microglia associated with plaques.
In spite of that fact that the specific stimuli driving microgliosis during disease 
may be heterogeneous, a common finding from our rodent in vitro and in vivo findings 
and AD brains is the increase in protein phospho-tyrosine levels. Our prior in vitro work
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has demonstrated that specific non-receptor tyrosine kinase activities including Lyn and 
Syk are involved in the oligomer-dependent activation of microglia (Sondag et al.. 2009) 
which correlated well with the increased phospho-tyrosine immunoreactivity observed in 
the intracerebroventricular infused animals. In vitro studies using monocytic lineage cells 
(McDonald et al., 19c8; Combs et al., 2001a; Bamberger et al., 2003) and microglia 
(Combs et al., 1999; Sondag et al., 2009) have demonstrated that fibrillar A(3 stimulates a 
specific increase in overall protein tyrosine phosphorylation. Although numerous tyrosine 
kinases are expressed in microglia and it is likely that the temporal profile of kinase 
activities changes during chronic oligomer stimulation. During disease, stimulation with 
fibril, oligomer or other ligands may be superimposed (Sondag et al., 2009). Based upon 
the human disease and in vitro data, we demonstrated that active forms of non-receptor 
tyrosine kinases, Src and Lyn, are increased in reactive microglia. Indeed, the microglial 
phospho-Src and phospho-Lyn immunoreactivity changes observed in the AD brains is, 
to the best of our knowledge, a new contribution to the field. Thus, we have begun to 
identify particular kinase activities that may be responsible for the increase in 
phosphotyrosine immunoreactivity and microgliosis during disease.
This common change of increased forms of active non-receptor tyrosine kinases 
in the rodent and human findings served as the rationale for selecting a somewhat broad 
specificity agent, dasatinib, for its ability to attenuate the function of several different 
kinases, in particular the Src family members (Lombardo et al., 2004; Das et al., 2006). 
The ability of dasatinib to limit protein phospho-tyrosine changes and cytokine secretion 
suggests that targeting kinase activity is a viable anti-inflammatory strategy for treating 
AD. It is interesting to note that limiting tyrosine kinase-dependent microgliosis is not the
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only attractive reason for targeting these enzymes. For instance, tau phosphorylation is 
regulated via activity of the tyrosine kinase Abl modulating Cdk5 activation in a 
transgenic mouse model of AD (Alvarez et ah, 2004; Cancino et ah, 2009). Very 
recently, another tyrosine kinase inhibitor anti-cancer drug, imatinib, has been shown to 
target gamma-secretase activating protein as a therapeutic approach for Alzheimer’s 
disease in a rodent model (He et ah, 2010). Not surprisingly, recruitment of Src and Abl 
tyrosine kinases to APP has been demonstrated (Trommsdorff et ah, 1998). Prior work 
has also verified an increased association of Src with APP in human diseased brains 
(Austin et ah, 2009). Although our intracerebroventricular infusions, transgenic animals 
and in vitro studies, focused on oligomer and fibril stimulated mechanism of 
proinflammatory microgliosis in AD, it is likely that a heterogeneous mixture of changes 
during disease offers the possibility that inhibition of this class of kinases will be 
attractive from a number of different therapeutic perspectives.
Both in vitro data and in vivo experiments demonstrated that an oligomeric 
preparation of Ap corresponding roughly to the size of SDS-stable trimer/tetramers at 
initial stimulation could drive microgliosis via a tyrosine kinase-dependent mechanism 
that correlated with a similar change in protein tyrosine phosphorylation in human 
diseased brains. Despite the fact that the oligomeric Ap was delivered in a HDL solution 
to ensure its stability as an oligomeric preparation while in the pump, it is possible that 
the multimeric species changed after infusion into the brain over the time course of 14 
day administration resulting in higher molecular weight species. However, 
immunohistochemical analyses using anti-oligomer antibodies to observe for oligomeric 
Ap immunoreactivity strongly suggests by the thioflavin negative. A ll /111 positive nature
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ol the deposited A|3, that the peptide was retained in an oligomeric and not fibrillar form. 
The possibility that higher order multimers and possibly some undetected fibrils did 
accumulate in the tissue during the infusion period along with, perhaps, co-deposition of 
endogenous Af3, cannot be excluded. With the understanding that there may be some 
multimeric species of A[3 involved, along with the SDS-stable trimeric/tetrameric infused 
A(3, the changes observed in microgliosis and the ability of dasatinib to attenuate those 
changes remain novel and relevant to A|3-dependent microglial changes during disease. 
With regard to human disease, we certainly do not exclude the likelihood that fibrillar 
deposits of A(3 are also potent stimuli of microglia. As already mentioned, increased 
protein phospho-tyrosine staining from both AD brains and transgenic mouse models 
(Wood and Zinsmeister, 1991; Frautschy et ah, 1998) have characterized microglial 
activation in association with A|3 plaques. Furthermore, prior work has demonstrated that 
fibrils also stimulate microglia in vitro via tyrosine kinase-mediated mechanisms 
(McDonald et ah, 1997; Combs et ah, 1999). However, histologic analysis of human 
brains demonstrated that some reactive microglia were associated with oligomeric A3 as 
well, a finding not widely reported. In addition, many phospho-tyrosine immunoreactive 
microglia in diseased brains were not associated with any observable A3 deposits 
suggesting that non-deposited A3 oligomers or other molecules could be activating these 
cells as well. Therefore, we propose that oligomers are one of the stimuli driving 
microgliosis during disease but recognize a likely role of fibrils as well as possible still 
unnamed ligands. It is for this reason that we chose to examine fibril activation as well 
both in vitro and in the APP/PS1 model. As expected, both oligomers and fibrils could
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activate microgiia via Src family activation in our rodent studies correlating well with the 
increased pSrc/pLyn immunoreactivity from AD brains.
Validation that an orally available, FDA approved drug, dasatinib, was efficacious 
in in vivo study supports the idea of therapeutic tyrosine kinase inhibition for AD. 
Dasatinib (commercially, Sprycel) is used for treating chronic myeloid leukemia (Shah et 
ah, 2004) and has the ability to cross the blood brain barrier (Porkka et al., 2008). We 
have demonstrated that it also attenuates AP-dependent proinflammatory microgliosis 
and inhibits disease relevant non-receptor tyrosine kinases, and improves cognitive 
performance.
The effect of decreasing microglial active Src and brain TNFa levels does not 
necessarily prove that these changes were responsible for the improved cognitive 
performance observed in the transgenic ir use model of AD with subcutaneously infused 
dasatinib. However, the in vitro data clearly demonstrated that dasatinib treatment and 
Src inhibition led to attenuated TNFa secretion providing correlative evidence that Src 
inhibition in microglia in vivo contributed to the decrease in TNFa observed. Moreover, 
recent human data using TNFa neutralizing drugs demonstrated cognitive improvement 
in AD patients (Tobinick and Gross, 2008) suggesting that diminished TNFa levels in the 
mice could have contributed to the cognitive improvements observed. We also appreciate 
that dasatinib treatment may effect a number of other kinases in vitro and in vivo and 
numerous cells may express Src. Non-receptor Src family tyrosine kinases are expressed 
widely in the mammalian CNS and are known to play a role in proliferation and 
differentiation of the CNS (Yoshimura et al., 1981; Alema and Tato, 1987; Haltmeier and 
Rohrer, 1990; Meeker et al., 1991; Wongetal., 1992; Barone and Courtneidge, 1995;
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Taylor and Shalloway, 1996; Broome and Hunter, 1997; Klinghoffer et al., 1999; 
Tatosyan and Mizenina, 2000). Indeed, Src family kinase activities are crucial for 
synaptic plasticity, including learning and memory (Grant et al., 1992; Maness, 1992; 
Grant and Silva, 1994; Kojima et al., 1997; Sinai et al., 2010). Therefore any strategy to 
manipulate activity of these enzymes in the brain should be carefully considered. By 
demonstrating specificity of dasatinib for Src versus the related family member Lyn in 
vivo as well as a clear improvement in cognitive performance, we suggest that reagents 
such as dasatinib can form the basis for not only human testing consideration but, more 
importantly, for further drug development.
This study intentionally focused on animals at 13 months of age with established 
plaques and reactive microglia to test the efficacy of our anti-inflammatory strategy in 
late-stage disease. However, it will be important in future work to determine if a strategy 
of kinase inhibition can attenuate or delay behavioral decline or microgliosis in earlier 
stage disease. Although our longitudinal assessment in these mice suggested that 
phosphotyrosine immunoreactive microglia correlated with increased fibrillar plaque 
deposition, our prior work and our infusion data indicated that soluble oligomeric forms 
of A[3 were also potent stimuli of microglia responsible for initiating a unique type of 
tyrosine kinase-based signaling response (Sondag et al., 2009). Therefore, fully 
determining the specific signaling pathways involved in different forms of A(3 stimulation 
of microglia may offer a strategy for inhibiting specific tyrosine kinase activities at 
different disease time points to maximally produce anti-inflammatory effects.
Based on all the data thus far, we suggest amyloid-dependent microgliosis occurs 
via a Src kinase activation mechanism and this pathway is an important therapeutic target
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in the prevention of AD. This work dealt with using a general non-receptor tyrosine 
kinase inhibitor, dasatinib, that shows affinity for a number of non-receptor tyrosine 
kinases including Src, Lyn, Fck and Yes. Dasatinib has higher affinity for Src and our in 
vitro and in vivo findings suggest that the drug has been effective in attenuating active 
Src levels. However, in human disease, another non-receptor tyrosine kinase, Lyn has 
been implicated in reactive plaque associated microglia. The Src family member, Lyn 
kinase has an important role in regulating immune cell phenotype. Lyn has been shown to 
physically associate with a number of hematopoetic cell surface receptors including BCR., 
CD40, LPS receptor and the FceRl complex. Kinase dead mice, with mutations 
associated with loss of activity of Lyn show attenuated autoimmune disease, normally 
associated with Lyn deficiency (Verhagen et ai., 2009) indicating a role of Lyn in B Cell 
regulation. Lyn also is an important target role in prostate cancer therapies (Goldenberg- 
Furmanov et al., 2004). Therefore, identifying the Lyn selective inhibitor to attenuate 
microgliosis in general and not just associated with AD, may prove to be crucial for 
therapeutically targeting several diseases. Based upon the observations that AD brains 
showed increased levels of pLyn in tissue lysates as well as plaque-associated 
immunoreactivity of active, phcsphorylated Lyn, Lyn cannot be excluded as a valid target 
for attenuation of Ap-associated microgliosis (Fig. 33). Following a high throughput 
screening kinase assay, four novel compounds were identified based upon their in vitro 
ability to inhibit Lyn. We further defined their ability to inhibit Lyn kinase basally as well 
in stimulated microglial in vitro models. We demonstrated that LDDN- 0003499, one 
compound in particular, was able to inhibit basal active, phosphorylated Lyn levels in the 
BV2 microglial cell line. LDDN-0003499 also decreased le vels of active Lyn and Src in
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Ap and LPS stimulated microglia. Although this study was a characterization of the drugs 
in an in vitro system, there is a further need to modulate these drugs for in vivo use by 
characterization of particular specificities. At this point, we conclude that Lyn is also a 
relevant target for attenuating disease-associated microgliosis and propose that drug 
dependent strategies such as this we has s undertaken may provide selective agents, for 
assessing the importance of Lyn vs. Src for contributing to microgliosis.
Since microglia are the primary immune cells in CNS, they have been implicated 
in a number of neurodegenerative disorders. As mentioned earlier, many pro- 
inflammatory and trophic factors are thought to be produced by activated microglia in 
vitro (Giulian ef al., 1986; Hetier et al., 1988; Mallat et al., 1989; Sawada er ah, 1989; 
Elkabes et a;., 1996; 1/liwa et ah, 1997). Microglia derived cytokines have been reported 
to be elevated in many cases besides Alzheimer’s disease, including traumatic spinal cord 
lesion, traumatic brain injury, stroke, HIV-infection and multiple sclerosis (Lindholm et 
ah, 1987; Griffin et ah, 1989; Fagan and Gage, 1990; Merrill and Chen, 1991; Woodroofe 
et ah, 1991; Taupin et ah, 1993; Buttini et ah, 1994; Merrill and Benveniste, 1996; 
Bartholdi and Schwab, 1997; Benveniste, 1997). Despite of the findings that the stimuli 
involved or the ligands responsible for microglial activation in disease conditions may be 
different, the fact remains that modulating microglial phenotype in order to attenuate pro- 
inflammatory effects becomes imperative in prevention of the adverse effects of 
microgliosis in all these diseases. Hence it is important to understand the mechanism(s) 
underlying the activation of microglia for pharmacologic intervention studies.
Stimulation by fl-amvloid peptides results in increased expression ofCD40 on microglia 
leading to elevated TNF-a secretion (Tan et ah, 1999b; Tan et ah, 2000). Microglial
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activation by either A[), CD40 ligand (CD40L) or LPS has been shown to involve 
activation of the MAPK pathway as well (Combs et al„ 1999; Tan et ah, 1999a). Lyn 
kinase has been shown to be involved in regulation of M APK activation in microglia 
(Combs et ah, 1999). Src is also reported to take part in regulation of MAPK in T cells, 
following stimulation (Tsuji-Takayama et ah, 1997). Although, the mechanism of 
Src/MAPK regulation are complex, it appears that, in general, Src activation leads to 
downstream activation of MAP kinase, and production of neurotoxic and pro- 
inflammatory mediators. (Singer et ah, 2011) (Figure 33). The process can also occur 
through acti vation of the PBKinase pathway (Combs et ah, 1999). Src may also activate 
other signaling mediators like the JAK/STAT pathway leading to inflammatory gene 
expression (Simon et ah, 2002; Simeone-Penney et ah, 2008). Therefore, the signaling 
responses of pro-inflammatory signaling includes Src, activation is complex and is likely 
stimulant dependent. Our data indicates a role for Lyn and Src kinases in reactive 
microgliosis in AD. The retrospective studies involving NSAIDs possibly suggest that 
microglial inhibition is the basis of the benefic al effects in AD. Clearly, further 
experiments are needed to better understand the signaling cascade and the intracellular 
interactions involved for driving microglial activation during disease. It is only by 
detecting the intrinsic mechanisms of microglial activation that the most relevant target 
and therefore, drugs can be developed.
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Figure 33. Schema*
,C ° f Srt/Lyn signaling pathway
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APPENDIX





ALL Acute Lymphoblastic Leukemia
ANOVA Analysis of Variation
ApoE Apolipoprotein E
ATP Adenosine Tri Phosphate
CaC12 Calcium Chloride
CCL-2 Chemokine (C-C motif) ligand 2
CD40 Cluster of Differentiation 40
CML Chronic Myelogenous Leukemia
CNS Central Nervous System
co2 Carbon di Oxide
Cox Cyclooxygenase




DM EM Dulbecco's Modified Eagle Medium
EDTA Ethylene diamine Tetraacetic acid
EGFR Epidermal Growth Factor Receptor
EGTA Ethylene Glycol Tetraacetic Acid
ERK Extracellular Regulated Kinase
FAD Familial Alzheimer's Disease
FAK Focal Adhesion Kinase
FBS Fetal Bovine Serum
FDA Federal Drug Administration
FGFR Fibroblast Growth Factor Receptor
FITC Fluorescein Isothiocyanate
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gp 130 Glycoprotein 130
HDL High Density Lipoprotein
HEPES (4-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid )
HFIP Hexafluoroisopropanol
HIV Human immunodeficiency virus




LDDN Laboratory of Drug Discovery in Neurodegeneration
EPS Lipopolysaccaride
MAPK Mitogen Activated Protein Kinase
MCI Mild Cognitive Impairment
MCP-1 Monocyte Chemotactic Protein-1
MHC Major Histocompatibility Complex





NS AID Non-Steroidal Anti-Inflammatory Drug
OD Optical Density
PAGE Poly Acrylamide Gel Electrphoresis
PBS Phosphate Buffered Saline
PDGFR Platelet Derived Growth Factor Receptor
PET Positron Emission Tomography









PVDF Poly Vinylidene Di Flouride
RIPA RadioImmunoPrec-ipitaticn Assay
SAD Sporadic Alzheimer's disease
SD Standard Deviation
SDS Sodium Dodecyl Sulphate
SEM Standard Error of Mean
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STAT Signal Transducer and Activator of Transcription
TBS Tris-Buffered Saline
TBS-T Tris-Buffered Saline Tween-20
Tg Transgenic
TGF Transforming Growth Factor
TNF Tumor Necrosis Factor
Tyr Tyrosine
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor Receptor
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